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Evidence shows that consumption of a Mediterranean diet can lower the risk of 
all-cause and cause-specific mortality suggesting that this diet has an overall effect on 
health.  Antioxidants found within olive oil, the primary source of fat in the 
Mediterranean diet, may be leading contributors to the decreased disease risk.  More 
specifically, hydroxytyrosol (HT), one of the most active and powerful antioxidants 
found in olive oil, has the ability to increase total antioxidant status and lower levels of 
lipid peroxidation.  In addition to a healthy diet, physical activity decreases the risk of 
cardiovascular morbidity and mortality; however, aerobic exercise of sufficient intensity 
or duration can induce oxidative stress.  Therefore, the purpose of this study was to 
investigate the effects of 6 weeks of HT supplementation on antioxidant status and 
markers of inflammation in healthy, recreationally active males before and throughout 
acute aerobic exercise bouts.  Using a randomized, double-blind, repeated-measures, 
placebo-controlled design, sixty-one (n=61) participants were randomly assigned to 
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consume a placebo (PLA), low dose of HT (LHT, 50 mg/day), or high dose of HT (HHT, 
150 mg/day).  Throughout the course of the study, the participants performed four time 
trial rides (TT1-TT4) on cycle ergometers.  TT1 occurred before supplementation, TT2 
halfway through the supplementation period, and TT3 and TT4 occurred in the sixth 
week and final two days of supplementation.  Blood was drawn prior to (pre) and just 
before termination (end) of each time trial to measure markers of antioxidant status and 
inflammation during exercise.  We did not observe significant main effects for treatment 
on any of the markers for antioxidant status (TEAC) or for markers of inflammation 
(oxLDL, CRP, 8IP, TNFα, IL-6, IL-10, IL-1β, or IL-1ra).  Significant treatment-by-time 
interactions occurred for CRP, 8IP, and IL-6 although significant treatment differences in 
these measures were not detected.  We conclude that chronic and acute HT 
supplementation does not improve antioxidant status nor decrease markers of 
inflammation in this population at rest, during, or following exercise. 
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Cardiovascular disease is one of the leading causes of death in industrialized 
nations and the second leading cause of death worldwide (Patrick & Uzick, 2001).  
However, epidemiological studies show that persons who consume a Mediterranean diet 
have a lower risk of all-cause and cause-specific mortality suggesting that this diet has an 
effect on overall health (Bogani et al., 2007; Carluccio et al., 2003; Cicerale et al., 2010; 
Covas, 2007; Minich & Bland, 2008; Pellegrini et al., 2003; Psaltopoulou et al., 2004).  
Olive oil is the primary source of fat in the Mediterranean diet and is associated with 
lower incidences of coronary heart disease and other degenerative diseases (Covas, 2007; 
Pellegrini et al., 2003).  The antioxidants found in olive oil may be a primary contributor 
to decreased disease markers.  For instance, they have the ability to decrease plasma 
levels of oxidized LDL and improve oxidative stress markers including lipid 
hydroperoxides, malondialdehyde, and activity of endogenous antioxidant defense 
systems (Raederstorff, 2009; Liu et al., 2009).  More specifically, hydroxytyrosol (HT), 
one of the most active and powerful antioxidants found in olive oil, has the ability to 
increase total antioxidant status in rabbits and lower levels of isoprostanes and oxidized 
LDL, both markers of lipid peroxidation, in humans (Gonzalez-Santiago et al., 2006; 
Mastaloudis et al., 2001; Raederstorff, 2009; Vazquez-Velasco et al., 2010; Vincent & 
Taylor, 2006). 
In conjunction with a healthy diet, physical activity is also associated with a 
decreased risk of cardiovascular morbidity and mortality (Mataix et al., 2008).  Despite 
the associated health benefits of exercise, sufficient intensity or duration of physical 
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activity can generate reactive oxygen species, which can increase oxidative stress often 
associated with an inflammatory state (Teixeira et al., 2009).  Recent research has 
focused on the effects of quercetin, an antioxidant found in the skins of many common 
fruits and vegetables, and its possible role in decreasing exercise-related muscular 
damage and inflammation.  Although equivocal results have been found with quercetin 
supplementation, to-date little research exists on HT consumption in conjunction with 
aerobic exercise. 
Therefore the purpose of this study was to: 1) observe changes in total antioxidant 
status and markers of inflammation in human blood with regular daily HT 
supplementation; 2) observe effects of an acute aerobic exercise bout on antioxidant 
status and markers of inflammation with regular daily HT supplementation; 3) compare 
changes throughout the acute aerobic exercise bout with regular daily HT 
supplementation; and 4) determine if changes in antioxidant status and markers of 
inflammation were greater with a high dose of HT (150 mg/day) when compared to a low 





This study was a randomized, double-blind, repeated-measures placebo-controlled 
study.  The 61 participants were randomized into one of three groups for hydroxytyrosol 
(HT) supplementation:  placebo (PLA), low dose (LHT) of HT (50 mg/day), or high dose 
(HHT) of HT (150 mg/day).  A third party, Metronomia (Muenchen, Germany) 
performed the randomization to preserve researcher and participant blinding.  The 
algorithm attempted to evenly distribute the body weights of the participants in each 
supplementation group.  Participants entering the study and weighing less than 80 kg 
were assigned the lowest available study product number, and those participants entering 
the study and weighing greater than or equal to 80 kg were assigned the highest available 
study product number.   
Throughout the course of the nine-week study, the participants performed four 
time trial visits at the Exercise Physiology and Metabolism (EPM) Laboratory, Bellmont 
Hall, The University of Texas at Austin.  Each time trial consisted of a 20 km simulated 
bicycle ride on a stationary cycle-ergometer (Velotron RacerMate, Inc., Seattle, WA).  
The baseline time trial (TT1) was performed before study product distribution to the 
participant.  Participants performed a mid-point time trial (TT2) after three weeks of 
supplementation, and in the sixth week two consecutive time trials (TT3 and TT4, 
respectively) were performed on the final two days of supplementation. 
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At each time trial, venous blood was drawn two times throughout the visit from 
an antecubital vein using a catheter to obtain whole blood samples for measurement of 
antioxidant status and inflammatory markers.  The first blood draw was taken 30 minutes 
before exercise commenced (pre) and another blood draw immediately before the very 
end of the time trial course (end).  At TT2, TT3, and TT4, the pre blood draw was taken 
30 minutes after ingestion of the study product just before commencement of exercise.  
Measurements of antioxidant status and inflammatory markers were compared for each 
participant during each time trial visit.  The pre, or resting, measurements and changes 
during exercise were assessed across the length of the study for TT1, TT2, and TT3 to 
determine chronic effects of the study product.  Resting measurements and changes 
during exercise were also assessed between TT3 and TT4 to determine acute effects of 
the study product.  Antioxidant status and markers of inflammation were also contrasted 
against the measurements of the three different supplementation groups.  Measures of 
antioxidant status included:  Trolox Equivalent Antioxidant Capacity (TEAC) and uric 
acid.  Measures of inflammation included:  oxidized low-density lipoprotein (oxLDL), C-
reactive protein (CRP), 8-isoprostane (8IP), and cytokines (tumor necrosis factor alpha 
(TNFα), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 1-beta (IL-1β), and 
interleukin 1-receptor antagonist (IL-1ra)). 
Participants 
Prior to recruitment of participants, the study protocol and the Informed Consent 
to Participate in Research (Appendix A) was approved by the Institutional Review Board 
at The University of Texas at Austin.  Participants were recruited through posters placed 
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around the campus of The University of Texas at Austin and through the “Hire a 
Longhorn” website, an Internet-based classified ads system available to UT students.  
Qualification for recruitment included healthy participants who were recreationally active 
males between 20 and 35 years of age.  Those willing to participate contacted the study’s 
investigators at the EPM Laboratory via telephone and/or email to express interest in 
participation.  Participants were then scheduled for a screening visit. 
Study Supplement 
 The study supplement was manufactured and distributed by DSM Nutritional 
Products (Kaiseraugst, Switzerland).  The wastewater produced by olive oil 
manufacturing was utilized for extraction of HT as this wastewater contains a 
considerable amount of phenols that are washed off during the olive oil production 
process (Visioli & Galli, 1998).  The HT extracted from this process was placed into 
capsules containing 50 mg HT.  Participants were instructed to consume one packet each 
day and each packet contained three capsules of study product.  The PLA dose capsules 
contained only modified starch.  The LHT dose packet contained one capsule with 50 mg 
HT and two capsules with modified starch.  The HHT dose packet contained three 
capsules with 50 mg HT each, thus a total of 150 mg of HT. 
 After the baseline time trial, participants were assigned a study product number 
based on weight as previously described and given a two-week supply.  The study 
product was consumed for a total of six-weeks.  Participants were instructed to keep the 
study product refrigerated at all times and to consume one packet (3 capsules) of study 
product each morning with breakfast.  If it was after 2:00 PM, the participant was 
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instructed to skip that day’s dose and continue study product consumption the following 
morning.  Participants were instructed on compliance with consumption of the study 
product.  Compliance had to remain at or above 85% throughout the study period; 
therefore, participants could not skip more than one dose per week and had to consume 
36 of the 42 total dosages.  Skipped doses were to remain in the original packet and all 
packets, empty and full, as well as boxes were to be returned to the EPM Laboratory at 
the next appointment.  All participants met the minimum compliance level and the 
remaining study product was returned to DSM Nutritional Products. 
Dietary and Exercise Regimen 
 The participants in this study were instructed to maintain dietary logs (Appendix 
C) for 48 hours prior to each time trial and to avoid foods and beverages high in 
antioxidants.  Foods and beverages consumed before the first time trial were to be 
mimicked before the subsequent time trials to limit dietary influences.  Throughout the 
study period, participants were instructed to limit olive oil consumption to one tablespoon 
per day, coffee or tea to one cup per day, wine to two glasses per week, and chocolate 
bars to two per week.   
In the 24 hours prior to the time trial, participants were instructed to completely 
avoid the following foods as they contain a large amount of antioxidants that could 
interfere with interpretation of the study product’s effects:  coffee, tea, wine, chocolate, 
cherry tomatoes, broccoli, blueberries, and onions.  In this study, participants were given 
one bottle of vanilla-flavored Ensure® (Abbott Nutrition, Cleveland, OH), provided by 
the staff of the EPM Laboratory, which was to be consumed 10 hours before the 
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appointment time.  At this time, fasting commenced except for water and hydration 
maintenance was encouraged.  
Participants were instructed to maintain recreational activities throughout the 
course of the study, and strenuous exercise was to be avoided in the 24 hours prior to the 
time trials and safety blood draws.   
Participants recorded time of supplement consumption, physical activity, and 
overall physical and emotional wellbeing on a daily online log (Zoomerang, San 
Francisco, CA).  EPM Laboratory staff alerted participants via text message or phone call 
if the log was not completed by 6:00 PM each day. 
Health and Safety Procedures 
 An initial blood draw at the familiarization visit was performed to test for 
Hepatitis B and C.  Four milliliters of whole blood were drawn from an antecubital vein 
under sterile conditions using a Vacutainer® (BD, Franklin Lakes, NJ) serum separator 
tube at the familiarization visit.  Blood was allowed to mix for 15 minutes and then the 
tube was centrifuged at 1300 g for 15 minutes.  The tube was then stored in a biological 
hazard safety bag in a four-degree Fahrenheit refrigerator until picked up by personnel 
from an outside laboratory for testing (Quest Diagnostics, Irving, TX).  Test results were 
available online and reviewed by the study physician and EPM Laboratory staff before 
the subsequent visit.  No participants in this study tested positive for Hepatitis B or C.   
 Upon arrival to the EPM Laboratory for every visit, participants were asked if 
adverse events, including sickness and/or trauma, had occurred since the last visit.  These 
were documented by laboratory staff and reviewed by the study physician to determine if 
8 
related to the study product.  If the study physician deemed the adverse event a result of 
the study product and endangered the participant, the participant was excused from the 
study and recommended to visit his primary care physician or the study physician.  
However, no adverse events excused participants from this study. 
Test Administration 
SCREENING VISIT 
The screening visit took place at the Fitness Institute of Texas (FIT), Bellmont 
Hall, at The University of Texas at Austin.  During this visit, the participants read and 
signed the Informed Consent to Participate in Research.  Next, participants were asked to 
complete a Participation Health Research Screening Form (Appendix B) to determine 
inclusion and exclusion criteria.  If the participant answered “no” to questions regarding a 
medical history inclusive of kidney, liver, or cardiovascular conditions, then he was 
asked to fully participate in the study.  Medications taken by the participant for allergies, 
depression, and/or thyroid hormone imbalances were acceptable only if the dosage had 
been consistent for the past two months.  Medications for treatment of cardiac, lipid, or 
hypertensive conditions, or blood-glucose regulators excluded the participant from the 
study.   
If the participant met the criteria, then study investigators measured the 
participant’s height using a stadiometer, weight using a scale, and blood pressure using a 
sphygmomanometer.  Height and weight were used to assess body mass index (BMI).  
Participants were only asked to partake in the study if BMI was less than or equal to 30 
kg/m2 and if his blood pressure was less than or equal to 140 mmHg systolic over 90 
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mmHg diastolic.  If all criteria were met, then the remaining study visits were scheduled 
including one familiarization visit with Hepatitis B and C blood draw screening and four 
time trial (TT) visits. 
FAMILIARIZATION RIDE 
The purpose of this visit was to acquaint the participant with the cycle ergometer 
and computer-based time trial course.  This visit took place approximately one week prior 
to the baseline time trial.  The participant was instructed to fast for two hours prior to the 
appointment time and arrive at the EPM Laboratory in loose, comfortable clothing and 
athletic shoes.  Upon arrival, he was weighed and his weight recorded.  He was then 
fitted with a heart rate monitor (Polar Electro Inc., Lake Success, NY), and his resting 
heart rate was recorded after five minutes of sitting quietly.  Blood was drawn to check 
for Hepatitis B and C.  After the blood draw, the participant mounted the stationary 
Velotron cycle ergometer (RacerMate Inc., Seattle, WA) and adjustments for a 
comfortable fit were made and recorded.  The Velotron cycle-ergometer and compatible 
Computrainer software (RacerMate Inc., Seattle, WA) installed on Hewlett-Packard 
computer systems (Palo Alto, CA) was used for this study because the data extracted 
from use of the Velotron cycle ergometers is highly reproducible (Sporer & McKenzie, 
2007).  The participant was instructed to perform the 20 km time trial ride as fast as 
possible.  Heart rate and rating of perceived exertion (RPE) using the Borg scale were 
measured and recorded halfway through and right before the very end of the time trial 
course. Water was provided to the participant ad libitum.  Upon completion of the time 
trial course, the participant performed a cool down until his heart rate reached 120 bpm or 
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less.  Then he dismounted from the cycle ergometer and returned the heart rate monitor to 
the EPM Laboratory staff.  Instructions for the baseline time trial were given to the 
participant.   
TIME TRIALS (TT) 
One week after the familiarization ride, participants performed the baseline time 
trial ride (TT1).  Upon arrival, the EPM Laboratory staff asked the participant about his 
exercise, food, and study product compliance and recorded this in the participant’s 
binder.  Next a 20 gauge Teflon catheter, fitted with a three-way stopcock, was inserted 
into an antecubital vein under sterile conditions to draw blood.  The catheter was fitted 
with extension tubes and taped securely in place so that successive blood draws could 
easily be made throughout the visit while the participant was riding the cycle ergometer.  
A pre-exercise (pre) blood draw was performed prior to commencement of exercise.  A 
10 ml syringe was fitted to the end of the three-way stopcock, the stopcock was turned so 
that blood flowed into the syringe with suction, and filled completely with whole blood.  
Blood was drawn following this same procedure right before completion (end) of the 
time trial course.   
Five-milliliters of this blood was distributed between two 12 X 75 mm culture test 
tubes (Fisherbrand, Hampton, NH) of which 2 ml were distributed into a tube containing 
200 µl of ethylenediaminetetraacetic acid (EDTA) (24 mg/ml, pH 7.4) and 10 µM 
indomethacin, and the remaining 3 ml were distributed into a tube containing 200 µl of 
EDTA only. 
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The remaining 5 ml of blood were transferred to a Vacutainer® serum-separator 
tube (SST).  The collection tubes and SST were inverted five times and left on ice for 
approximately 40 minutes.  After incubation the three collection tubes were centrifuged 
at 3000 rpm for 10 minutes using an HS-4 rotor in a Sorvall RC6 centrifuge (Kendro 
Laboratory Products, Newtown, CT), and the SST was centrifuged at 1300 g for 15 
minutes with an IEC Cl31R Multispeed Centrifuge (Thermo Electron Corporation, 
Waltham, MA).  After centrifugation, the plasma and serum supernatant was extracted 
off the top and divided into the respective microcentrifuge storage tubes.  Twenty 
microliters of butylated hydroxyl toluene was added immediately before storage to the 
tube labeled 8-Isoprostane for assay purposes.  These tubes were stored in a -20°C freezer 
until set and then placed in a -80°C freezer until further analysis.   
After completion of the time trial, the participant cooled down until his heart rate 
dropped to 120 bpm or less.  He then sat in a chair while EPM Laboratory staff removed 
the catheter, cleaned the area with an alcohol swab, and then placed a cotton ball and 
bandage over the puncture site.  The participant was then provided a light snack.   
After TT1, the participant was then randomized based on his weight and two-
weeks of study product were distributed to him.  Verbal and written instructions were 
provided to the participant regarding expectations of the study and consumption of the 
study product. 
Test administration for the subsequent trials was repeated for TT2, after 21 days 
of supplementation, and TT3 and TT4, on days 41 and 42 of supplementation, 
respectively.  At these visits, the participant took the study product 30 minutes prior to 
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exercise commencement under the supervision of EPM Laboratory personnel.  TT3 and 
TT4 were performed on consecutive days in order to observe effects of an increased 
inflammatory response and any acute treatment effects of the study product. 
BLOOD TISSUE ANALYSIS 
 Antioxidant Status.  Antioxidant status was measured in serum using Trolox 
Equivalent Antioxidant Capacity (TEAC) (Cayman Catalog No. 709001, Ann Arbor, MI) 
The kit has an intra-assay percent coefficient of variation (%CV) equal to 3.40% and 
inter-assay %CV equal to 3.00%.  The capacity of the antioxidants in the serum sample to 
prevent oxidation of ABTS® (2,2’-azinobis-3-ethylbenzothiazoline-6-sulphonic acid) is 
measured relative to Trolox.  A value is then assigned to the degree of discoloration 
yielding the TEAC measure (Morillas-Ruiz et al., 2006).  Uric acid was converted from 
mg/dl to mM and subtracted from TEAC to yield adjusted TEAC. 
 Uric Acid.  Uric Acid was measured in serum by enzymatic determination using 
Uric Acid Reagent (Raichem, Cliniqa, CA).  The kit has an intra-assay %CV equal to 
0.89% and inter-assay %CV equal to 1.00%.   
 Oxidized Low-Density Lipoprotein.  Oxidized low-density lipoprotein (oxLDL) 
in blood serum was allowed to bind to β2glucoprotein-I to form an oxLDL-β2GGPI 
complex, then measured using an Elisa sandwich assay (Cayman EIA Catalog No. 
10007893, Ann Arbor, MI).  The kit has an intra-assay %CV equal to 4.80% and inter-
assay %CV equal to 10.00%.  Results of this assay were calculated using MasterPlex® 
ReaderFit: Curve-Fitting Software for ELISA Analysis (Hitachi Solutions America, 
South San Francisco, CA). 
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C-Reactive Protein.  C-reactive protein (CRP) was measured using an 
immunoturbidimetric assay to assess antibody and antigen immunoprecipitation 
complexes found in blood serum (Raichem, Catalog No. 87545).  The kit has an intra-
assay %CV equal to 4.10% and inter-assay %CV equal to 3.20%.   
 8-Isoprostane.  Levels of 8-isoprostane (8IP), which indicates oxidation of tissue 
phospholipids by reactive oxygen species (ROS) in serum samples, were measured 
enzymatically at an absorbance of 420 nm (Cayman EIA Catalog No. 516351, Ann 
Arbor, MI).  The kit has an intra-assay %CV equal to 11.70% and inter-assay %CV equal 
to 16.40%.  Results of this assay were also calculated using MasterPlex® ReaderFit: 
Curve-Fitting Software for ELISA Analysis (Hitachi Solutions America, South San 
Francisco, CA).    
 Cytokines.  Concentrations of various cytokines, inflammatory response 
molecules, in serum samples were assessed using Millipore High Sensitivity Multiplex 
Cytokine Assay kit (Millipore, Billerica, MA) with the Bio-Plex 200 multiplex 
suspension array system, using Luminex xMAP detection technology (Luminex Corp., 
Austin, TX).  The cytokines analyzed include:  TNFα, IL-6, IL-10, and IL-1β.  IL-1ra 
was measured using Millipore Multiplex Cytokine Assay kit (Millipore, Billerica, MA).  
Results of this assay were calculated using MILLIPLEX Analyst Software (Millipore, 
Billerica, MA).  Intra-assay %CV for IL-1ra, TNFα, IL-6, IL-10, and IL-1β were 4.60%, 
3.49%, 3.51%, 3.31%, and 3.11%, respectively and inter-assay %CV were 6.00%, 3.78%, 
4.48%, 11.84%, and 2.16%, respectively. 
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All assays were performed at the conclusion of the fielding; unblinding occurred 
after completion of all assays.  Assay protocols were followed as described by the 
company with each participant’s time point ran in duplicate.  Intra-assay %CV for the 
assays ran in our lab was calculated by dividing the standard deviation by the mean of the 
duplicate measure.  The %CV for the assay was then averaged together.  This was the 
case for TEAC, Uric Acid, oxLDL, CRP, and 8IP; whereas, %CV for the cytokines was 
calculated by MILLIPLEX Analyst Software.  The %CV in our lab for the assays are as 
follows: TEAC – 5.15%, Uric Acid – 1.66%, oxLDL – 7.35%, CRP – 6.47%, 8IP – 
2.15%, IL-1ra – 1.21%, TNFα – 0.55%, IL-6 – 0.76%, IL-10 – 2.92%, and IL-1β – 0.60%  
DATA ANALYSIS 
All data were analyzed using PASW 18.0 for Windows (SPSS Inc., Chicago, IL).  
Descriptive statistics were performed and included:  mean, standard deviation, standard 
error of the mean, skewness and kurtosis.  All data except 8IP and TEAC were skewed, 
with skewness or kurtosis ≥ 1.5, and transformed using a log transformation before 
running comparative statistics.  Comparisons were made between pre values of TT1, 
TT2, and TT3 to assess chronic effects of the study product at rest, and changes within 
time trials (end – pre) were also compared across TT1, TT2, and TT3 to determine 
chronic effects of the study product during exercise.  Comparisons were made between 
pre values of TT3 and TT4 to observe acute treatment effects of the study product at rest, 
and changes within time trials (end – pre) were also compared between TT3 and TT4 to 
determine acute effects of the study product on consecutive days of exercise.  Data were 
analyzed both between and within treatments using repeated-measures ANOVA by 
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treatment-by-time.  Changes (Δ) between time trials were compared using a oneway 
ANOVA.  Where significance was found, post hoc analyses using LSD with no 
correction for multiple comparisons were performed.  Differences were considered 




Chronic effects of the study product on antioxidant status and markers of 
inflammation were examined by treatment between TT1, TT2, and TT3.  Treatments 
included:  placebo (PLA), low dose HT (LHT), and high dose HT (HHT).  TT1 occurred 
before distribution of the study product (day 0), TT2 after 21 days of supplementation, 
and TT3 after 41 days of supplementation.  Measurements of antioxidant status and 
markers of inflammation during each time trial were taken at rest (pre) and just before 
completion of exercise (end).  Comparisons were made between pre values of TT1, TT2, 
and TT3 to assess chronic effects of the study product at rest, and changes within time 
trials (end – pre) were also compared across TT1, TT2, and TT3 to determine chronic 
effects of the study product during exercise.   
Acute effects of the study product on antioxidant status and markers of 
inflammation were examined by treatment between TT3 and TT4.  TT4 occurred 24 
hours after TT3 (i.e. day 42 of supplementation).  Comparisons were made between pre 
values of TT3 and TT4 to observe acute treatment effects of the study product at rest, and 
changes within time trials (end – pre) were also compared between TT3 and TT4 to 
determine acute effects of the study product on consecutive days of exercise. 
Data was analyzed both between and within treatments using repeated-measures 
ANOVA by treatment-by-time.  Changes (Δ) between time trials were compared using a 
oneway ANOVA.  Where significance was found, post hoc analyses using LSD with no 
correction for multiple comparisons were performed.  
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TEAC 
There was no significant chronic treatment effect or treatment-by-time interaction 
between TT1, TT2, and TT3 at rest or during exercise.  Also, no significant acute 
treatment effects were found between TT3 and TT4 at rest or during exercise.   
Table 1.  Descriptive data by time point and treatment for TEAC (mM). 
 
Values are means ± SE. 
 
Figure 1.0.  Resting TEAC levels (mM) at TT1, TT2, and TT3 between treatments.  Bars 
represent means ± S.E.  No significant chronic treatment effect or treatment-by-time 
interaction was found. 
 
TT1 1.03 ± 0.06 1.03 ± 0.06 0.92 ± 0.06 0.96 ± 0.05 0.96 ± 0.04 0.88 ± 0.06
TT2 1.08 ± 0.07 1.04 ± 0.08 0.99 ± 0.05 0.95 ± 0.04 1.01 ± 0.05 1.00 ± 0.04
TT3 0.95 ± 0.07 1.03 ± 0.07 0.89 ± 0.04 1.02 ± 0.06 0.93 ± 0.05 0.96 ± 0.03
TT4 1.06 ±0.08 1.03 ± 0.07 1.04 ± 0.05 1.02 ± 0.06 1.02 ± 0.05 1.03 ± 0.04
PLA LHT HHT























Figure 1.1.  Changes in TEAC (mM) during exercise at TTI, TT2, and TT3 between 
treatments.  Bars represent means ± S.E.  No significant chronic treatment effect or 
treatment-by-time interaction was found. 
 
 
Figure 1.2.  Resting TEAC levels (mM) at TT3 and TT4 between treatments.  Bars 














































Figure 1.3.  Changes in TEAC (mM) during exercise at TT3 and TT4 between treatments.  




There was no significant chronic treatment effect or treatment-by-time interaction 
between TT1, TT2, and TT3 at rest or during exercise.  Also, no significant acute 
treatment effects were found between TT3 and TT4 at rest or during exercise.   
Table 2.  Descriptive data by time point and treatment for oxLDL (ng/ml). 
 























TT1 228.31 ± 100.47 289.36 ± 139.68 247.01 ± 98.95 218.93 ± 80.08 270.91 ± 122.94 308.02 ± 131.57
TT2 223.32 ± 106.39 270.40 ± 138.61 199.00 ± 89.83 226.78 ± 97.35 247.67 ± 96.96 281.44 ± 113.55
TT3 249.32 ± 145.04 262.09 ± 138.67 209.44 ± 90.85 240.76 ± 88.43 215.30 ± 79.56 243.41 ± 88.56
TT4 230.53 ± 131.00 246.15 ± 122.55 230.45 ± 98.99 277.89 ± 120.78 204.84 ± 72.72 232.06 ± 80.44
LHT HHT




Figure 2.0.  Resting oxLDL levels (ng/ml) at TT1, TT2, and TT3 between treatments.  
Bars represent means ± S.E.  No significant chronic treatment effect or treatment-by-time 
interaction was found. 
 
 
Figure 2.1.  Changes in oxLDL (ng/ml) during exercise at TTI, TT2, and TT3 between 
treatments.  Bars represent means ± S.E.  No significant chronic treatment effect or 



















































Figure 2.2.  Resting oxLDL levels (ng/ml) at TT3 and TT4 between treatments.  Bars 
represent means ± S.E.  No significant acute treatment effect was found. 
 
 
Figure 2.3.  Changes in oxLDL (ng/ml) during exercise at TT3 and TT4 between 



















































There was no significant chronic treatment effect between TT1, TT2, and TT3 
resting CRP values, but a significant treatment-by-time interaction was found (p=.041).  
A post hoc analysis, however, showed no specific differences between treatments.  Upon 
further analysis, we found significance in the Δ between TT1 and TT3 resting CRP levels 
(p=.018) with the post hoc analysis showing HHT is significantly lower than LHT 
(p=.006).  No significant chronic treatment effect or treatment-by-time interactions were 
found during exercise between TT1, TT2, and TT3.  Also, no significant acute treatment 
effects were found between TT3 and TT4 at rest or during exercise. 
Table 3.  Descriptive data by time point and treatment for CRP (mg/L).  
 
Values are means ± SE. 
 
END
TT1 1.13 ± 0.30 1.27 ± 0.36 0.95 ± 0.18 1.05 ± 0.20 1.81 ± 0.53 2.18 ± 0.66
TT2 1.03 ± 0.20 1.11 ± 0.21 1.54 ± 0.54 1.58 ± 0.53 1.17 ± 0.27 1.31 ± 0.32
TT3 1.45 ± 0.38 1.62 ± 0.42 1.50 ± 0.30 1.60 ± 0.31 0.98 ± 0.25 1.20 ± 0.35






Figure 3.0.  Resting CRP levels (mg/L) at TT1, TT2, and TT3 between treatments.  Bars 
represent means ± S.E.  Brackets appear above time trials in which significance was 
found between Δ values.  *Significantly lower than LHT (p=.006). 
 
 
Figure 3.1.  Changes in CRP (mg/L) during exercise at TTI, TT2, and TT3 between 
treatments.  Bars represent means ± S.E.  No significant chronic treatment effect or 























Figure 3.2.  Resting CRP levels (mg/L) at TT3 and TT4 between treatments.  Bars 
represent means ± S.E.  No significant acute treatment effect was found. 
 
 
Figure 3.3.  Changes in CRP (mg/L) during exercise at TT3 and TT4 between treatments.  























There was no significant chronic treatment effect between TT1, TT2, and TT3 
resting 8IP values, but a significant treatment-by-time interaction was found (p=.003).  
The post hoc analysis, however, showed no specific differences between treatments.  
Upon further analysis, we found significance in the Δ between TT1 and TT2 resting 8IP 
levels (p=.001) with the post hoc analysis showing LHT is significantly higher than PLA 
(p=.001) and HHT (p=.005).  We also found significance in the Δ between TT2 and TT3 
resting 8IP levels (p=.012) with the post hoc analysis showing LHT is significantly lower 
than PLA (p=.003).  There was a significant chronic treatment-by-time interaction 
between TT1, TT2, and TT3 during exercise (p=.031) with a post hoc analysis showing 
LHT significantly lower than PLA in TT2 (p=.027).  No significant acute treatment 
effects were found between TT3 and TT4 at rest or during exercise.  
Table 4.  Descriptive data by time point and treatment for 8IP (pg/ml). 
  
Values are means ± SE. 
PRE END PRE END
TT1 35.30 ± 2.52 34.99 ± 3.33 31.93 ± 2.37 33.24 ± 2.26 33.54 ± 2.25 32.41 ± 2.22
TT2 31.53 ± 2.27 34.45 ± 2.51 37.16 ± 2.34 33.61 ± 3.04 31.86 ± 1.77 34.23 ± 1.90
TT3 32.88 ± 2.16 35.28 ± 2.96 31.66 ± 1.90 32.86 ± 1.99 30.23 ± 1.73 32.99 ± 2.02





Figure 4.0.  Resting 8IP levels (pg/ml) at TT1, TT2, and TT3 between treatments.  Bars 
represent means ± S.E.  Brackets appear above time trials in which significance was 
found between Δ values.  ‡Significantly higher than PLA (p=.001) between TT1 and TT2.  
◊Significantly higher than HHT (p=.005) between TT1 and TT2. ∞Significantly lower 
than PLA (p=.003) between TT2 and TT3.  
  
 
Figure 4.1.  Changes in 8IP (pg/ml) during exercise at TTI, TT2, and TT3 between 
treatments.  Bars represent means ± S.E.  †Significantly lower than PLA (p=.027) in TT2. 















































Figure 4.2.  Resting 8IP levels (pg/ml) at TT3 and TT4 between treatments.  Bars 
represent means ± S.E.  No significant acute treatment effect was found. 
 
 
Figure 4.3.  Changes in 8IP (pg/ml) during exercise at TT3 and TT4 between treatments.  














































There was no significant chronic treatment effect or treatment-by-time interaction 
between TT1, TT2, and TT3 at rest or during exercise.  A significant acute treatment 
effect was found in the Δ between TT3 and TT4 for resting TNFα values (p=.045) with 
the post hoc analysis showing LHT is significantly lower than HHT (p=.014).  No 
significant acute treatment effect was found during exercise between TT3 and TT4. 
Table 5.  Descriptive data by time point and treatment for TNFα (pg/ml). 
 
Values are means ± SE. 
 
Figure 5.0.  Resting TNFα levels (pg/ml) at TT1, TT2, and TT3 between treatments.  Bars 
represent means ± S.E.  No significant chronic treatment effect or treatment-by-time 
interaction was found. 
 
TT1 5.59 ± 0.64 7.21 ± 1.26 6.69 ± 0.43 7.83 ± 0.54 5.93 ± 0.49 7.48 ± 0.62
TT2 7.57 ± 2.26 10.14 ± 2.92 6.03 ± 0.43 7.63 ±0.69 5.37 ± 0.53 6.85 ± 0.69
TT3 7.08 ± 1.37 8.61 ± 1.54 6.51 ± 0.61 7.58 ± 0.64 5.32 ± 0.59 6.67 ± 0.58
TT4 6.64 ± 1.07 8.66 ± 1.67 5.97 ± 0.47 7.31 ± 0.63 5.65 ± 0.57 6.71 ± 0.68
PRE END
PLA LHT HHT






















Figure 5.1.  Changes in TNFα (pg/ml) during exercise at TTI, TT2, and TT3 between 
treatments.  Bars represent means ± S.E.  No significant chronic treatment effect or 
treatment-by-time interaction was found. 
 
 
Figure 5.2.  Resting TNFα levels (pg/ml) at TT3 and TT4 between treatments. Bars 
represent means ± S.E.  Brackets appear above time trials in which significance was 



























Figure 5.3.  Changes in TNFα (pg/ml) during exercise at TT3 and TT4 between 




There was no significant chronic treatment effect between TT1, TT2, and TT3 
resting IL-6 values, but a significant treatment-by-time interaction was found (p=.033).  
A post hoc analysis, however, showed no specific differences between treatments.  With 
further analysis, we found significance in the Δ between TT1 and TT3 resting IL-6 levels 
(p=.032) with the post hoc analysis showing HHT is significantly lower than PLA 
(p=.009).  There was no significant chronic treatment-by-time interaction between TT1, 
TT2, and TT3 during exercise.  A significant acute treatment effect was found in the Δ 
between TT3 and TT4 for resting IL-6 levels (p=.026) with the post hoc showing HHT is 
significantly higher than PLA (p=.009).   No significant acute treatment effect was found 
during exercise between TT3 and TT4. 
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Table 6.  Descriptive data by time point and treatment for IL-6 (pg/ml).  
 
Values are means ± SE. 
 
Figure 6.0.  Resting IL-6 levels (pg/ml) at TT1, TT2, and TT3 between treatments.  Bars 
represent means ± S.E.  Brackets appear above time trials in which significance was 
found between Δ values.  °Significantly lower than PLA (p=.009). 
 
TT1 1.43 ± 0.13 1.96 ± 0.13 1.50 ± 0.18 1.92 ± 0.15 1.74 ± 0.18 2.22 ± 0.14
TT2 1.71 ± 0.19 2.14 ± 0.19 1.49 ± 0.18 1.96 ± 0.14 1.65 ± 0.15 2.14 ± 0.12
TT3 1.72 ± 0.19 2.21 ± 0.17 1.55 ± 0.20 2.01 ± 0.16 1.63 ± 0.14 2.18 ± 0.11
TT4 1.62 ± 0.17 2.04 ± 0.16 1.50 ± 0.19 1.88 ± 0.18 1.72 ± 0.14 2.09 ± 0.12
PRE END
PLA LHT HHT





















Figure 6.1.  Changes in IL-6 (pg/ml) during exercise at TTI, TT2, and TT3 between 
treatments.  Bars represent means ± S.E.  No significant chronic treatment effect or 
treatment-by-time interaction was found. 
 
 
Figure 6.2.  Resting IL-6 levels (pg/ml) at TT3 and TT4 between treatments.  Bars 
represent means ± S.E.  Brackets appear above time trials in which significance was 






















Figure 6.3.  Changes in IL-6 (pg/ml) during exercise at TT3 and TT4 between treatments.  
Bars represent means ± S.E.  No significant acute treatment effect was found. 
 
IL-10 
There was no significant chronic treatment effect or treatment-by-time interaction 
between TT1, TT2, and TT3 at rest or during exercise.  Also, no significant acute 
treatment effects were found between TT3 and TT4 at rest or during exercise.   
Table 7.  Descriptive data by time point and treatment for IL-10 (pg/ml).  
 
Values are means ± SE. 
TT1 27.75 ± 12.04 36.03 ± 14.38 34.86 ± 17.06 37.06 ± 15.50 72.99 ± 38.67 71.76 ± 30.53
TT2 42.60 ± 18.79 76.25 ± 45.02 31.45 ± 17.65 37.05 ± 19.99 33.72 ± 13.57 42.20 ± 15.37
TT3 33.61 ± 9.51 50.46 ± 18.35 34.43 ± 14.96 42.61 ± 17.41 32.22 ± 10.80 42.63 ± 15.52
TT4 33.46 ± 10.14 41.89 ± 13.82 33.73 ± 18.23 37.54 ± 19.16 38.91 ± 14.07 40.95 ± 12.12
PRE END
PLA LHT HHT
PRE END PRE END
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Figure 7.0.  Resting IL-10 levels (pg/ml) at TT1, TT2, and TT3 between treatments.  Bars 
represent means ± S.E.  No significant chronic treatment effect or treatment-by-time 
interaction was found. 
 
 
Figure 7.1.  Changes in IL-10 (pg/ml) during exercise at TTI, TT2, and TT3 between 
treatments.  Bars represent means ± S.E.  No significant chronic treatment effect or 






















Figure 7.2.  Resting IL-10 levels (pg/ml) at TT3 and TT4 between treatments.  Bars 
represent means ± S.E.  No significant acute treatment effect was found. 
 
 
Figure 7.3.  Changes in IL-10 (pg/ml) during exercise at TT3 and TT4 between 























There was no significant chronic treatment effect or treatment-by-time interaction 
between TT1, TT2, and TT3 at rest or during exercise.  Also, no significant acute 
treatment effects were found between TT3 and TT4 at rest or during exercise.   
Table 8.  Descriptive data by time point and treatment for IL-1β (pg/ml).  
 
Values are means ± SE. 
 
Figure 8.0.  Resting IL-1β levels (pg/ml) at TT1, TT2, and TT3 between treatments.  Bars 
represent means ± S.E.  No significant chronic treatment effect or treatment-by-time 
interaction was found. 
 
TT1 0.40 ± 0.18 0.51 ± 0.19 0.23 ± 0.09 0.22 ± 0.09 0.55 ± 0.23 0.80 ± 0.30
TT2 2.39 ± 1.79 2.69 ± 1.98 0.33 ± 0.14 0.39 ± 0.17 0.40 ± 0.15 0.59 ± 0.27
TT3 1.55 ± 0.80 1.76 ± 1.01 0.54 ± 0.28 0.49 ± 0.22 0.66 ± 0.27 0.65 ± 0.26
TT4 1.30 ± 0.76 1.86 ± 1.10 0.32 ± 0.16 0.59 ± 0.26 0.61 ± 0.24 0.64 ± 0.24
PRE END
PLA LHT HHT

























Figure 8.1.  Changes in IL-1β (pg/ml) during exercise at TTI, TT2, and TT3 between 
treatments.  Bars represent means ± S.E.  No significant chronic treatment effect or 
treatment-by-time interaction was found. 
 
 
Figure 8.2.  Resting IL-1β levels (pg/ml) at TT3 and TT4 between treatments.  Bars 


























Figure 8.3.  Changes in IL-1β (pg/ml) during exercise at TT3 and TT4 between 
treatments.  Bars represent means ± S.E.  No significant acute treatment effect was found. 
IL-1ra 
There was no significant chronic treatment effect or treatment-by-time interaction 
between TT1, TT2, and TT3 at rest or during exercise.  Also, no significant acute 
treatment effects were found between TT3 and TT4 at rest or during exercise.  
Table 9.  Descriptive data by time point and treatment for IL-1ra (pg/ml).  
 
Values are means ± SE. 
TT1 26.01 ± 10.29 27.41 ± 9.47 10.32 ± 3.66 13.74 ± 4.46 16.60 ± 7.11 20.58 ± 8.36
TT2 31.47 ± 11.36 40.14 ± 12.98 10.16 ± 3.24 11.24 ± 3.29 17.96 ± 6.13 21.12 ± 6.83
TT3 31.00 ± 11.42 35.33 ± 11.71 11.23 ± 3.72 13.50 ± 3.44 18.25 ± 7.57 22.44 ± 7.60
TT4 30.84 ± 10.51 34.04 ± 10.10 10.29 ±3.46 10.96 ± 3.34 19.57 ±7.97 21.44 ± 6.80
PRE END
PLA LHT HHT
PRE END PRE END
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Figure 9.0.  Resting IL-1ra levels (pg/ml) at TT1, TT2, and TT3 between treatments.  
Bars represent means ± S.E.  No significant chronic treatment effect or treatment-by-time 
interaction was found. 
 
 
Figure 9.1.  Changes in IL-1ra (pg/ml) during exercise at TTI, TT2, and TT3 between 
treatments.  Bars represent means ± S.E.  No significant chronic treatment effect or 


























Figure 9.2.  Resting IL-1ra levels (pg/ml) at TT3 and TT4 between treatments.  Bars 
represent means ± S.E.  No significant acute treatment effect was found. 
 
 
Figure 9.3.  Changes in IL-1ra (pg/ml) during exercise at TT3 and TT4 between 


























 It is widely accepted that a Mediterranean diet contributes to a decreased disease 
risk and has an effect on overall health (Bogani et al., 2007; Carluccio et al., 2003; 
Cicerale et al., 2010; Covas, 2007; Minich & Bland, 2008; Pellegrini et al., 2003; 
Psaltopoulou et al., 2004).  Olive oil is the primary source of fat in the Mediterranean diet 
and contains a considerable amount of phenols, which primarily contribute to decreasing 
oxidative stress and inflammation associated with many disease states (Cicerale et al., 
2010; Covas, 2007; McDonald et al., 2001).  In addition to a healthy diet, physical 
activity is also related to a decreased risk of cardiovascular morbidity and mortality 
(Mataix et al., 2008).  Although exercise is beneficial, sufficient intensity or duration of 
an acute bout can induce oxidative stress (Teixeira et al., 2009).  This occurs because a 
high demand is placed on skeletal muscle mitochondria to produce energy for muscle 
contraction and movement.  The mitochondria become overpowered and release highly 
reactive oxygen species, which increase the inflammatory response (Mataix et al., 1998).   
Therefore, the purpose of this study was to investigate the chronic and acute 
effects of a daily low dose (LHT, 50 mg/day) or daily high dose (HHT, 150 mg/day) of 
HT, one of the highest concentrated phenols found in olive oil, for 6 weeks over placebo 
conditions at rest and during exercise on total antioxidant status and markers of 
inflammation in healthy, recreationally active males.  To the best of our knowledge, no 
study-to-date has examined the effects of HT supplementation at rest or during exercise 
over a 6-week period on antioxidant status and markers of inflammation in this 
population.  Our primary findings indicate that there was no significant treatment effect 
42 
on markers of total antioxidant status – TEAC – and inflammation – oxLDL, CRP, 8IP, 
and cytokines – at rest or during exercise with 6 weeks of LHT or HHT.  We did, 
however, observe significant treatment-by-time interactions for resting values of CRP, 
8IP, and IL-6 over the 6-week period although no significant treatment differences were 
detected.   
The change between TT1 and TT3 we observed in resting levels of CRP over the 
6 week period was significantly lower for the HHT group compared to the LHT group, 
which actually increased over the course of the study.  PLA also increased, but this was 
not significant.  No significant differences, however, were observed with acute HT 
supplementation between TT3 and TT4 resting values.  While our data shows a chronic 
decrease with a high dose of HT, this is similar to the significant decrease observed in 
patients with stable coronary heart disease (CHD) after consuming 50 ml of virgin olive 
oil daily for 3 weeks (Fito et al., 2008), which would equate to approximately 1.37 mg 
HT (Miro-Casas et al., 2003).  We would expect the same decrease in CRP from TT1 to 
TT3 with LHT as this dose is well above the amount given in the aforementioned study; 
however, this was not the case.  Compared to the patients with stable CHD, our sample 
included healthy, recreationally active males who engaged in weekly exercise but were 
not trained athletes, thus we would not expect elevated resting levels of CRP as 
epidemiological studies have reported the odds ratio for elevated CRP levels decreases 
with increased physical activity (Ford, 2002).  Mean resting CRP levels throughout our 
study were well within normal limits of 0.068 to 8.2 mg/L (Tietz, 1995), and no 
significant elevations were observed during exercise between groups.  We did see 
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elevated resting CRP levels at TT4, which occurred 24 hours after TT3, suggesting a 
persistent inflammatory effect of the exercise.  Although the increased CRP levels were 
not significant, this agrees with Liesen et al. (1977) in which they detected a significant 
increase in CRP levels 1 and 2 days after prolonged physical exercise in young, healthy 
males. 
CRP levels typically correlate with IL-6 levels (Du Clos & Mold, 2004; Vincent 
& Taylor, 2006) and thus, we observed similarly low, normal, resting IL-6 values 
throughout the study period.  Although we did not observe significant differences 
between groups with the treatment-by-time interaction, the change in resting IL-6 values 
over the 6 week period was significantly lower for the HHT group compared to the PLA 
group, thus HHT decreased from TT1 to TT3 compared to an increase in PLA.  The 
opposite effect, however, was seen in acute changes in resting values between TT3 and 
TT4.  HHT increased compared to a decrease in PLA from TT3 to TT4.  We also 
observed a significant increase in resting TNFα values from TT3 to TT4 in HHT 
compared to a decrease in LHT, and no significant chronic effect from TT1 to TT3 was 
observed for TNFα values at rest.  Whether the significance found is a result of HT is yet 
to be determined as values were still well within the normal range (Himmerich et al., 
2006).  A lack of significant chronic effects as well as acute effects were present for 
resting levels of IL-10, IL-1β, and IL-1ra.  This would be expected in this population 
because cytokines are not produced unless provoked by inflammatory agents, microbial 
invasion, or injury (Cerami, 1992).  
44 
It is likely to conclude that HT has no effect on the cytokines we measured during 
exercise because no significant chronic nor acute treatment effects were found between 
groups during time trials.  Our findings support that of Teixeira et al., (2009), who 
concluded that their antioxidant cocktail, consisting of vitamins and minerals taken daily 
for 4 weeks, did not offer protection against exercise-induced inflammation as measured 
by IL-6 in trained kayakers after a 1000 m simulated kayak race.  On the other hand, 
Vassilakopoulos et al., (2003) observed significant decreases in pro-inflammatory 
cytokines – IL-1β, IL-6, and TNFα – in post-exercise measurements after daily 
consumption for one month of a supplement containing various antioxidants such as 
vitamins, allopurinol and N-acetylcysteine, in healthy, untrained males.  With these 
studies, it is difficult to isolate the effects of the ingredients without ruling out a 
synergistic effect among them all. 
While we did not test for significant increases above baseline during exercise, IL-
6 did increase 43% or more during exercise in all time trials and all treatments.  This 
finding is in line with what is reported in the literature regarding release and subsequent 
increase of IL-6 from the contracting muscles during aerobic exercise (Gleeson, 2007).  
IL-6 is released regardless of skeletal muscle tissue damage and is related to the intensity, 
duration, mass of muscle recruited, and endurance capacity.  The literature suggests that 
IL-6 released during exercise exhibits anti-inflammatory properties by stimulating the 
release of anti-inflammatory cytokines, IL-10 and IL-1ra, as well as soluble TNFα 
receptors, a naturally occurring inhibitor of TNFα (Petersen & Pedersen, 2005).  IL-6 
regulates TNFα levels as demonstrated in IL-6-deficient knockout mice with increased 
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resting levels of TNFα who required multiple doses of recombinant IL-6 to attneuate high 
TNFα levels (Mizuhara et al., 1994; Petersen & Pedersen, 2005).  While slight, we also 
observed increases, although not directly tested for significance, during exercise in 
TNFα, IL-1ra, and IL-10 (except for a small and insignificant decrease in the PLA group 
at TT1) which could imply the effects of IL-6 released during exercise.      
Another marker of inflammation we examined for this study was oxLDL, and we 
did not observe any significant chronic or acute treatment effects for resting levels of 
oxLDL.  The current literature shows a strong association between HT and decreased 
oxLDL both in vitro and in vivo.  For example, an inverse dose-response relationship 
exists between higher concentrations of HT and lower levels of peroxyl radical 
destruction of the LDL particle in vitro (Aruoma et al., 1998).  In studies on rabbits, the 
ability of LDL to resist Cu2+-induced oxidation was significantly increased when fed a 
modified standard diet containing 10% virgin olive oil and 7 mg/kg of oleuropein, a 
polyphenol similar in structure to HT and comparable to the average daily biophenol 
intake of a human consuming a Mediterranean diet, daily for 6 weeks when compared to 
rabbits on the standard diet (Coni et al., 2000).  Vazquez-Velasco et al. (2010) observed 
significantly lower oxLDL levels in healthy human subjects after 3 weeks of consuming 
45-50 mg/day of HT added to 10-15 g/day of sunflower oil when compared to the control 
group consuming only sunflower oil.  While our study included doses above typical daily 
ingestion of HT, we did not find a chronic nor acute significant decrease in resting 
oxLDL levels between treatments despite the current research.  There was no observable 
significant chronic or acute treatment effect during exercise on oxLDL.  The present 
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study does not agree with findings from Liu et al. (1999), who observed an increase in the 
susceptibility of LDL to oxidation after a marathon race.  The literature suggests that 
lipid hydroperoxides, as measured by oxLDL, increase during exercise (Urso & Clarkson, 
2003); although we did not assess the sole effects of exercise on oxLDL, the changes 
during exercise were positive (aside from a negative change during TT1 in LHT) 
suggesting oxidative stress did occur during the exercise protocol.  Despite a lack of 
significant findings with oxLDL, another marker of lipid peroxidation, 8IP, yielded some 
favorable results.  
Even though there were no significant differences between groups with the 
treatment-by-time interaction, the change in resting 8IP values over the 3 week period 
from TT1 to TT2 was significantly higher for LHT compared to PLA and HHT; however, 
the opposite occurred in changes from TT2 to TT3 in which LHT was significantly lower 
than PLA.  Although this finding was significant, the increase and subsequent decrease of 
8IP in LHT was still within normal ranges of resting 8IP values (Wang et al., 1995), so it 
is improbable that HT had any real effect on this inflammatory marker.  The literature 
suggests an inverse dose-response relationship exists between the rate of excretion of an 
isoprostane, specifically 8-iso-PGF2a, and amounts of phenolics, or HT, ingested 
(Cornwell & Ma, 2008; Covas, 2007; Tuck & Hayball, 2002; Visioli et al., 2000; Visioli 
et al., 2001).  This was not the case for our study – no treatment effect nor dose-response 
was observed.  Similarly, Leger et al., (2005) examined the acute effects of HT and did 
not see a significant variation in 8-iso-PGF2a urinary exretion during four-days of HT 
supplementation, in which the dose administered is typical of a southern European diet.  
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The subjects in this study, however, were Type I diabetics whose basal 8-iso-PGF2a levels 
were already elevated three-fold; therefore, the authors attributed the lack of a significant 
finding in isoprostane excretion to the elevated basal levels.  Although our participants’ 
8IP levels were normal, we still did not observe any significant acute changes in resting 
8IP levels between TT3 and TT4. 
Unlike the increases in 8IP during exercise observed in the literature, we observed 
a significant decrease in 8IP levels during exercise with LHT in TT2; however, this 
decrease was very diminutive (approximately 3.5 pg/ml).  Mastaloudis et al. (2001) 
observed a significant increase in F2-isoprostane levels of trained endurance runners 
following strenuous exercise when compared to the sedentary control protocol, and Goto 
et al. (2007) also reported a significant increase in 8-isoprostane levels following high 
intensity exercise.  The mild and moderate intensity exercise protocols used in the latter 
study yielded insignificant differences among 8IP levels during exercise, which 
correspond to our findings.  Goto and colleagues concluded that their high-intensity 
protocol was enough to bring about oxidative stress as evidenced by 8IP, which presents 
a possibility that our exercise protocol was not intense enough to elicit such results with 
either chronic or acute supplementation. 
With the lack of significant findings between treatments for the markers of 
inflammation, it is probable to conclude that TEAC values were unaffected by the study 
product.  Antioxidant consumption or supplementation is expected to increase antioxidant 
status and consequently decrease markers of inflammation; however, we observed no 
significant chronic or acute treatment effects in TEAC at rest or during exercise.  Our 
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data, therefore, does not support that of Gonzalez-Santiago et al. (2006).  They found a 
significant increase in TEAC when rabbits’ diets were supplemented daily with 4 mg of 
HT/kg body weight for one month compared to the control group.  Thus, this presents a 
limitation of our study; the rabbits’ diets were standardized, and our participants’ diets 
were not even though they were instructed to mimic their diet in the 48 hours preceding 
each time trial visit.  Very little change was observed in TEAC levels at rest as well as 
during exercise throughout the course of the study.  Berzosa et al. (2011) found 
antioxidant status significantly higher post-exercise when compared to pre-exercise 
regardless of a maximal or submaximal exercise model.  We did not assess significance 
of end-exercise values compared to pre-exercise values; however, the change during 
exercise did not always increase.  Our TEAC values were corrected for uric acid, so it is 
likely that endogenous uric acid production increased just as much as TEAC during 
exercise yielding an insignificant change in TEAC between treatments.  Our data, 
therefore, more resembles that of Morillas-Ruiz and colleagues (2006) although they used 
trained cyclists versus our recreationally active group.  The authors did not observe an 
acute significant difference in TEAC values after trained cyclists performed an exercise 
bout at 70% VO2max both with and without an antioxidant beverage. 
In conclusion, no significant treatment effects were found on chronic or acute 
measures of antioxidant status and inflammation at rest or during exercise with 6 weeks 
of LHT or HHT supplementation compared to PLA.  We did observe significant 
treatment-by-time interactions for resting values of CRP, 8IP, and IL-6 over the 6-week 
period although no significant differences were detected between treatments.  Therefore, 
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it is probable to conclude that chronic and acute HT supplementation does not improve 
antioxidant status nor decrease markers of inflammation in this population at rest or 
during exercise.  This could be attributable to an already robust endogenous antioxidant 
defense as well as literature that report physically active individuals have lower chronic 
circulating levels of inflammatory biomarkers (Gleeson, 2007).  The case could also be 
made for the lack of a vigorous exercise protocol because inflammatory markers were not 
significantly increased during exercise.  Although participants performed subsequent 
days of exercise at TT3 and TT4 to examine possible amplified inflammatory effects of 
the exercise, the data suggests that this was not the case.  It is possible to argue that there 
could be accumulation of HT, which would make it difficult to differentiate the chronic 
from the acute observations since TT4 was conducted after 6 weeks of supplementation.   
Anecdotal evidence from our lab implies that HT remained in the system for up to 1 week 
after consuming the last dose.  Further studies should elucidate the acute effects of the 
antioxidant supplement prior to long-term ingestion.  Also, studies examining the effects 
of HT in sick and diseased populations in combination with exercise could prove to be 
beneficial in decreasing markers of inflammation both from a diet and physical activity 
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Cardiovascular disease is one of the leading causes of death in industrialized 
nations and the second leading cause of death worldwide (Patrick & Uzick, 2001).  
However, epidemiological studies show that persons who consume a Mediterranean diet 
have a lower risk of all-cause and cause-specific mortality suggesting that this diet has an 
effect on overall health (Bogani et al., 2007; Carluccio et al., 2003; Cicerale et al., 2010; 
Covas, 2007; Minich & Bland, 2008; Pellegrini et al., 2003; Psaltopoulou et al., 2004).  
Olive oil is the primary source of fat in the Mediterranean diet and is associated with 
lower incidences of coronary heart disease and other degenerative diseases (Covas, 2007; 
Pellegrini et al., 2003).  Because of its considerable benefits, researchers have begun to 
investigate the properties of olive oil that can attribute to the decreased risk of disease.  
For example, Fernández-Jarne et al. (2002) demonstrated that persons in the upper 
quintile of daily olive oil consumption had an 82% relative reduction in risk for a first 
non-fatal myocardial infarction even after adjustment for dietary and non-dietary 
confounders.  The antioxidants found in olive oil may be a primary contributor to 
decreased disease markers.  For example, hypercholesterolemic subjects fed olive oil 
consisting of 400 ppm of phenols for breakfast versus olive oil containing only 80 ppm of 
phenols exhibited a lower thrombogenic state, which is related to development of 
arteriosclerosis, two-hours after the meal (Ruano et al., 2007). 
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In conjunction with a healthy diet, physical activity is also associated with a 
decreased risk of cardiovascular morbidity and mortality (Mataix et al., 2008).  Despite 
the associated health benefits of exercise, sufficient intensity or duration of physical 
activity can generate reactive oxygen species, which can increase oxidative stress often 
associated with an inflammatory state (Teixeira et al., 2009).  This literature review will 
further investigate the properties of olive oil, its main antioxidant, hydroxytyrosol (HT), 
and how consumption can contribute to decreased oxidative stress and thus a decreased 
disease risk.  It will then describe oxidative stress induced by exercise and how 
antioxidant supplementation may alter various markers of antioxidant status and 
inflammation. 
Properties of Olive Oil 
CONTENTS 
 Shelf life of oils is determined by antioxidant content, fatty acid composition of 
the lipids, and storage temperature (Mateos et al., 2003).  Olive oil has a high 
monounsaturated fatty acid (MUFA) content comprised of 56-84% oleic acid (Galli & 
Visioli, 1999).  This fatty acid exhibits protective properties against free radical damage 
and contributes to a longer shelf life when compared to polyunsaturated fatty acids 
(PUFA), such as linoleic acids that are typically found in other seed oils (Owen et al., 
2000).   
In addition to the high MUFA concentration, olives are a particularly rich source 
of phenolic antioxidants (McDonald et al., 2001).  A high phenolic content protects the 
integrity of the oil from oxidation, termed oxidative stability, caused by environmental 
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stressors, such as ultraviolet (UV) radiation and high ambient temperatures (Visioli et al., 
2001; Tuck & Hayball, 2002).  Of all the phenols contained in olive oil, the three in 
highest concentration are the glycoside oleuropein, tyrosol, and hydroxytyrosol (3,4-
dihydroxyphenyl ethanol, HT) (Tuck & Hayball, 2002).  Concentrations of oleuropein 
and HT, both available as pure compounds, can be as high as 800 mg/kg in extra virgin 
olive oil and 2 g/100 g d.w. in olives (Carluccio et al., 2003; Visioli et al., 2001).  In 
addition, the type of phenol, whether it is lipophilic or hydrophilic, can further enhance 
protection from oxidation in virgin olive oil.  For example, Baldioli and colleagues 
(1996) found a higher hydrophilic content that was strongly correlated with oxidative 
stability (r = 0.97) in 48 different virgin olive oils.  The question remains, however, can 
the protection against free radicals provided by high MUFA and phenolic concentrations 
be transferred in vivo? 
In a study conducted by Huertas et al. (1999), rats were fed a semi-synthetic and 
isoenergetic diet that varied depending on the type of fat and antioxidant for 6 and 12 
months from weaning.  All rats were given either 50 mg/kg/day of virgin olive oil, 
sunflower oil, or sunflower oil supplemented with an antioxidant, coenzyme Q10 
(CoQ10).  After 6 or 12 months of daily olive oil consumption, cardiac muscle 
mitochondria were analyzed for the ratio of PUFA to MUFA as well as hydroperoxide 
free-radical assault on that tissue.  Regardless of age, the cardiac muscle mitochondrial 
membrane fatty acid profile reflected the type of oil consumed; there was an increase in 
mitochondrial levels of oleic acids and a decrease in mitochondrial linoleic acid levels 
when fed virgin olive oil.  Conversely, there was an increase in linoleic acid levels and a 
58 
decrease in oleic acid levels within the mitochondrial membrane fatty acid profile of rats 
consuming sunflower oil.  The production of hydroperoxides tripled at 12 months of age 
in the diet containing only sunflower oil when compared to the virgin olive oil group.  
When CoQ10 was added to the sunflower oil, the production of hydroperoxides was 
significantly less compared to the sunflower oil group.  The researchers concluded that 
addition of CoQ10 as a dietary supplement along with enrichment of the cardiac muscle 
mitochondrial membrane makeup by MUFA consumption, significantly protected against 
hydroperoxide attack on the aged mitochondrial membrane.  Considering that olive oil’s 
high MUFA and phenolic concentration can exert effects in vivo, many researchers have 
investigated its possible effects on attenuating similar disease processes. 
EFFECT ON DISEASE 
High oxidative stress levels in humans have been linked to disease, specifically 
atherosclerosis and cancer (McDonald et al., 2001).  Because of the lower incidences of 
coronary heart disease and other degenerative diseases associated with olive oil 
consumption, researchers have begun to examine its effects on specific markers of 
oxidative stress.  Chronic consumption of olive oil phenolic compounds can alter markers 
of oxidative stress by creating a favorable adjustment in lipid composition, platelet and 
cellular function, and a reducing inflammation (Cicerale et al., 2010).   
Resistance of LDL to oxidation, a marker of atherogenesis, was increased when 
oleuropein, an olive oil polyphenol, was added to the diet of rabbits.  The rabbits were 
fed a modified standard diet containing 10% virgin olive oil and 7 mg/kg of oleuropein 
daily for 6 weeks. Compared to the control group consuming the standard diet, the added 
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virgin olive oil and oleuropein group exhibited increased ability of LDL to resist 
oxidation through a Cu2+-stimulated LDL conjugated diene formation (Coni et al., 2000).  
In another case, 23 hypertensive patients in a double-blind, crossover study were fed a 
diet high in MUFA from extra virgin olive oil for six months and then crossed over to a 
diet high in PUFA from sunflower oil for the remaining six months.  When compared to 
PUFA, blood pressure and required daily doses of anti-hypertensive medication were 
significantly lower after MUFA consumption (Ferrara et al., 2000).  
Furthermore, the type of olive oil, virgin or refined, can also contribute to 
decreased markers of oxidative stress.  Fito et al. (2005) observed lower levels of 
oxidized lipoproteins and lipid peroxides and an increase in glutathione-peroxidase 
activity in males with stable coronary heart disease who consumed virgin olive oil.  
Subjects in this study consumed 50 ml of virgin olive oil per day for three-weeks and 
then consumed an equal amount of refined olive oil per day in another three-week period.   
Likewise, phytochemicals in olive oil and red wine inhibit endothelial adhesion 
molecule expression, a marker of atherosclerosis, thus partially explaining cardio-
protective benefits from a Mediterranean diet (Carluccio et al., 2003).  To demonstrate, 
rabbits fed an olive leaf extract versus rabbits fed a high lipid diet for six weeks exhibited 
a down-regulation of atherosclerotic and inflammatory markers (Wang et al., 2008).   
When compared to refined olive oil and other seed oils, virgin olive oil has a 
significantly higher phenolic antioxidant content and its polyphenol content can range 
from 100 mg/kg to 1000 mg/kg (D’Angelo et al., 2001; Owen et al., 2000).  This 
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literature review will now further investigate one of the main phenols in olive oil, 
hydroxytyrosol. 
Hydroxytyrosol (HT) 
PHYSICAL AND CHEMICAL PROPERTIES 
 HT is a lipo- and hydro-soluble compound found within olives, and it is one of the 
most active and powerful antioxidants (Carrasco-Pancorbo et al., 2005; Deiana et al., 
1999; Feng et al., 2011; Gordon et al., 2001).  HT can range from 85-169 mg/kg in olive 
oil, and the progressive hydrolysis of oleuropein yields accumulation of HT and elenolic 
acid upon storage (Petroni et al., 1995; Cornwell & Ma, 2008; Granados-Principal et al., 
2010).  The antioxidant capability of phenols depends on the hydrogen-donating ability 
and successive stabilization of free radical molecules.  Free radicals are atoms or 
molecules with an unpaired electron in an open shell configuration.  By attempting to pair 
the unpaired valance electron, these molecules cause damage by oxidizing surrounding 
structures, specifically carbohydrates, lipids, proteins, and nucleic acids (Halliwell et al., 
1995).  Quiles et al. (2002) have suggested that the number of hydroxyl groups and 
insertion of an ethylenic group between the phenyl ring and carboxylate group determines 
the efficacy of these phenolics.  HT is similar in structure to tyrosol with one hydroxyl 
group and one ethylenic group, except HT contains an additional hydroxyl group in the 
meta position (Tuck & Hayball, 2002).  Caffeic acid, a similar compound also found in 
olive oil, contains only two hydroxyl groups and no ethylenic groups.  Due to the lower 
number of hydoxyl and ethylenic groups, neither tyrosol nor caffeic acid have been 
shown to be as effective as HT in their antioxidant capabilities.   
61 
 Once absorbed and metabolized, antioxidants exert their effects in vivo.  HT is 
absorbed in the small intestine in a dose-dependent manner and excreted in urine in 
concentrations ranging from 30-60% up to two-hours after ingestion along with its 
metabolites homovanillic acid and homovanillic alcohol (Fitó et al., 2007; Granados-
Principal et al., 2010; Schwedhelm et al., 2003; Tuck & Hayball, 2002).  Peak 
concentration of HT in plasma has been observed at 32 minutes after consuming 
approximately 25 ml of virgin olive oil; however, others have observed a peak 
concentration in plasma approximately one-hour after ingestion (Fitó et al., 2007; Miro-
Casas et al., 2003).  How much olive oil needs to be consumed to obtain an effective dose 
of HT?  The concentration of HT found in olive oil is outlined below. 
VOLUME FOUND IN OLIVE OIL   
The volume of antioxidants found in olive oil is indicative of its quality and 
stability, and the concentration of antioxidants varies depending upon the level of 
processing, ripeness of olives at harvest, and climate (Petroni et al., 1995).  Because 
virgin olive oil is less refined, it has the highest concentration of total raw phenolics with 
values ranging from 130-350 mg/kg and concentrations of hydroxytyrosol ranging from 
2.6 – 27.0 mg/kg (Fitó et al., 2007; Quiles et al., 2002).  With almost 80% of the phenolic 
compounds lost in the refining process, olive wastewater is also a potent source for 
phenolic compounds (Manna et al., 2005).  Regardless of the source, researchers are 
using antioxidants derived from olive oil to better observe their effects on the various 
markers of oxidative stress.    
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ANTIOXIDANT CAPACITY AND EFFECT ON DISEASE 
 HT and its derivatives possess antioxidant, anti-thrombotic, anti-atherogenic, and 
anti-inflammatory properties, which contribute to attenuation of disease processes.  They 
have the ability to decrease plasma levels of oxidized LDL and improve oxidative stress 
markers including lipid hydroperoxides, malondialdehyde, and activity of endogenous 
antioxidant defense systems such as glutathione peroxidase (Raederstorff, 2009; Liu et 
al., 2009).   
Quiles et al. (2002) investigated the protective effects of HT, tyrosol, and caffeic 
acid on human prostate epithelium (PC3) because of this tissue’s susceptibility to 
oxidative stress.  The authors specifically measured oxidative damage to lipids and DNA 
when PC3 cells were incubated with hydrogen peroxide (H2O2).  No cytotoxic effects at 
pharmacological concentrations were observed on the human prostate cells when first 
treated with varying concentrations of HT, tyrosol, or caffeic acid for 24 hours.  When 
compared to control cells containing no phenolics and no H2O2 in the medium, a 12-fold 
increase in DNA damage was observed in cells treated with 60 µM of H2O2.  However, a 
dose-response decrease in DNA damage to cells was observed with increasing amounts 
of HT (10 µM, 50 µM, 100 µM, or 250 µM).  Compared to tyrosol and caffeic acid, cells 
incubated in HT exhibited significantly less DNA damage at the given doses.  Lipid 
peroxidation in PC3 cells incubated in HT was significantly less than controls and those 
treated with tyrosol or caffeic acid, but no dose-response effects with HT were observed.  
Thus, HT exhibited protective effects against oxidation of PC3 cells in vitro but not 
always in a dose-dependent manner. 
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Furthermore, a study by Kies and colleagues (2007) reported a dose-response 
relationship in male rat diaphragm muscle tissue with greater force production and a 
greater percent of protection when incubated with increasing doses of HT (0 µM, 10 µM, 
25 µM, 50 µM, 100 µM, and 300 µM) and exposure to 1 mM H2O2 in vitro.  H2O2 
decreases initial force in the absence of HT; thus increased protection is exhibited in the 
presence of increasing amounts of HT.  Another study conducted by Manna et al. (1997) 
showed HT-induced protection of intestinal cells against oxidative damage.  Micromolar 
concentrations of HT (250 µmol/L) completely protected caco-2 intestinal cells from 
ROS assault induced by 10 mmol/L of H2O2 or 10 U/L of xanthine oxidase in vitro.  The 
authors of this study concluded that dietary consumption of olive oil polyphenols might 
reduce the risk of oxidative stress-related gastrointestinal diseases.   
This has led other researchers to investigate the effects of HT on other oxidative 
stress-induced diseases, in particular atherosclerosis.  Because HT diminishes the 
cytokine-induced up-regulation of vascular adhesion molecules in human endothelial 
cells in culture, it was suggested that HT might reduce atherogenesis in vivo (Quiles et 
al., 2002).  Also a study conducted by Petroni and others (1995) showed that 
concentrations of HT ranging from 100-400 µM completely inhibited platelet aggregation 
when induced by adenosine diphosphate (ADP) or collagen in vitro.  At a dose of 400 
µM, HT prevented collagen-induced aggregation of platelets and inhibited production of 
thromboxane-B2 by stimulated platelets. 
Another free radical associated with atherogenesis is peroxynitrite, the product of 
excess nitric oxide (NO*) reacting with the superoxide radical (O2*-).  NO* is a necessary 
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physiological molecule, however, excess production can lead to chronic inflammation 
and cardiovascular disease via peroxynitrite damage.  Peroxynitrite provokes 
peroxidation of lipids, depletes antioxidant systems, and causes DNA damage.  The 
beneficial effects of HT to scavenge peroxynitrite have been confirmed in vitro, however, 
this effect in vivo is yet to be achieved (Deiana et al., 1999).   
Although HT has demonstrated beneficial effects in reducing inflammation by 
scavenging free radicals both in vitro and in vivo, some researchers have shown a pro-
oxidant effect with chronic HT consumption.  For example, Faine et al. (2006) found a 
pro-oxidant effect on cardiac tissue of male Wistar rats after consuming HT twice per 
week for one month.  The rodents were divided into four groups: control, olive oil (7.5 
ml/kg), isolated oleic acid (3.45 ml/kg), and isolated HT (7.5 mg/kg) consumption.  The 
rodents were gavaged twice a week with the respective treatment for a period of 30 days, 
and then lipid profiles in the blood and cardiac tissue were analyzed.  Olive oil 
consumption showed a significant difference in improving the lipid profile, elevating 
HDL cholesterol, and diminishing LDL cholesterol concentrations.  Conversely, a low-
dose of isolated HT elicited an undesirable pro-oxidant effect in cardiac tissue of the rat 
model by increasing lipid hydroperoxide concentration as well as the ratio of lipid 
hydroperoxide to superoxide dismutase, an endogenous free radical scavenger.  
Moreover, an increase in the development of atherosclerotic lesions, total cholesterol, and 
circulating monocytes were seen when apo-E deficient mice were given high quantities of 
HT, 10 mg/kg/day, for a period of 10 weeks.  Acin et al. (2006) concluded that isolated 
phenolic-enriched products could be potentially harmful given the results of their study.   
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Exercise and Free Radical Formation 
Considering that antioxidants such as HT are typically associated with increased 
health benefits, but too much may be detrimental, the question arises can aerobic exercise 
yield similar confounding results?  Epidemiological studies over the years have linked 
physical activity with decreased risk of cardiovascular morbidity and mortality; however, 
a paradox exists (Mataix et al., 2008).  Oxidative stress is present in many disease states, 
and it is also a consequence of aerobic exercise.  Aerobic exercise places a high demand 
on skeletal muscle mitochondria to produce energy for muscle contraction and 
movement.  The influx of electrons, associated with the high-oxygen demands for 
physical activity, can overpower the mitochondria.  Highly reactive oxygen species are 
then released because the last step of oxidative phosphorylation cannot be properly 
utilized (Mataix et al., 1998).  Electrons leak out between transfers around complex-I and 
complex-III on the electron transport chain and interact with surrounding oxygen forming 
the superoxide anion.  Superoxide dismutase (SOD), one of several endogenous 
enzymatic antioxidants, reacts with the superoxide anion forming hydrogen peroxide, a 
less offensive ROS, and oxygen (Mataix et al., 2008).  Endogenous antioxidant systems 
typically combat the released ROS; however, if the endogenous antioxidant system is 
inadequate compared to the presence of pro-oxidants, oxidative stress can occur and 
trigger an inflammatory response activated by the interaction of ROS and skeletal muscle 
tissue (Viguie et al., 1993; Manna et al., 1999; Powers et al., 2004).  The inflammatory 
response occurs post-exercise because exercise-induced muscle damage signals 
neutrophils to remove cellular debris, such as damaged muscular proteins.  Monocytes 
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and macrophages are also summoned to the area, where they produce more ROS and pro-
inflammatory cytokines, such as interleukin-1 (IL-1), tumor necrosis factor-alpha 
(TNFα), and interleukin-8 (IL-8), leading to overproduction of pro-oxidants.  This puts 
the system into an imbalance, thereby increasing oxidative stress and amplifying the 
inflammatory response even further (Morillas-Ruiz et al., 2006; Teixeira et al., 2009). 
Previous research on the exercise-induced inflammatory response and subsequent 
state of oxidant imbalance led Alessio and colleagues (2000) to measure markers of 
oxidative stress with exhaustive aerobic exercise and non-aerobic isometric exercise.  The 
purpose of their study was to determine the different exercise effects on lipid 
peroxidation, protein oxidation, and total antioxidant status.  After each exercise bout, 
evidence of oxidative stress was present in the blood of the 12 healthy subjects.  Protein 
carbonyls were significantly increased post-exercise in the exhaustive aerobic exercise 
model, whereas, in the non-aerobic isometric exercise model, lipid hydroperoxides were 
significantly increased post-exercise.  Total antioxidant status was significantly increased 
post exhaustive aerobic exercise versus pre-exercise values, but this was not significantly 
different with isometric exercise.  The authors determined that various markers of 
oxidative stress are associated with different exercise models, and this may be 
attributable to the differing metabolic demands of each. 
It is possible, however, that exercise-induced inflammation can be beneficial 
although inflammation is strongly associated with increased chronic disease risk.  While 
acute aerobic exercise in untrained animals induces oxidative stress, adaptation with 
endurance exercise training may increase antioxidant status and reduce oxidant enzymes 
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(Leeuwenburg & Heinecke, 2001).  Similarly, a study conducted by Mataix et al. (1998) 
observed an increase in glutathione peroxidase, an inherent antioxidant system found in 
skeletal muscle, after aerobic exercise training.  In addition, physically active individuals 
have lower chronic circulating levels of inflammatory biomarkers, and thus a reduced 
chronic disease risk over their lifetimes (Gleeson, 2007).  However, similar to pro-
oxidant effects with high doses of HT, an acute bout of prolonged and sustained aerobic 
exercise can induce ROS production that surpasses the endogenous antioxidant system, 
leading to oxidative stress, even in well-adapted, elite endurance athletes (Teixeira  et al., 
2009).  Accordingly, with the right dose of antioxidant(s), there may be a way to combat 
the oxidative stress resultant of an acute bout of aerobic exercise.  It may be possible to 
increase overall antioxidant status to attenuate a rise in ROS without stimulating a pro-
oxidant effect.  The following section will discuss how antioxidant supplementation can 
be used to contest ROS. 
Antioxidant Supplementation 
Antioxidants reduce ROS damage by significantly reducing the rate of oxidation, 
usually through donation of an electron to the ROS (Cesari et al., 2004).  To slow 
oxidative stress, endogenous antioxidant systems must be fully developed to protect 
against destruction of healthy cells and tissues.  The endogenous defense systems can be 
supplemented exogenously from natural as well as synthetic sources.  Naturally occurring 
polyphenols, flavonoids, and vitamins are typically found in fruits and vegetables.  
Vitamins C and E and other antioxidants including quercetin, epigallocatechin gallate 
(EGCG), and juice extract from pomegranates and cherries, have been studied to 
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determine effects on diminishing exercise-related muscle damage and soreness and 
improving exercise performance.  Quercetin is an antioxidant found in the skins of many 
common fruits and vegetables.  Davis et al. (2010) studied aerobic exercise performance 
with quercetin supplementation and found the supplement to elicit a significant increase 
in ride time to fatigue and VO2max in fit but untrained young adults.  It is hypothesized 
that the increase in VO2max and ride time to fatigue is attributable to increased 
mitochondrial biogenesis (Hao et al., 2010).  Biogenesis can result in an increased 
number of mitochondria as well as a denser mitochondrial matrix.  This allows for greater 
distribution of the expected output at a given workload thereby attenuating the leakage of 
ROS. 
In another study, Bigelman et al. (2010) tested six weeks of quercetin 
supplementation on physical performance in ROTC cadets.  The authors measured 
VO2peak as a potential indicator of increased mitochondria because previous research 
showed an increase in mRNA expression of SIRT1 and PGC-1α, both co-activators of 
mitochondrial biogenesis, an increase in mitochondrial density, and increase in run time 
to exhaustion in mice (Davis et al., 2009).  Unfortunately, the authors found no 
significant increase in VO2peak, nor other measures of physical performance:  the Army 
Physical Fitness Test, Baumgartner Modified Pull-Up Test, Wingate Anaerobic Test, and 
a 36.6-m sprint.   
Cureton and colleagues (2009) had similar findings.  Thirty recreationally active 
young men were assigned to either placebo or quercetin supplementation for a minimum 
of 7 days.  Subjects performed a VO2peak test and a 10 min cycling test for maximum 
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work output, which was then followed by one hour of submaximal cycling.  The authors 
found no statistically significant difference in VO2peak or performance measures between 
supplement groups in young, untrained men, therefore, no observable increase in 
muscular oxidative capacity. 
To measure the benefits of antioxidants on the human body, it is necessary to 
understand the mechanism of action.  Important questions to be raised:  Are the cells and 
tissues utilizing the antioxidants?  And are the antioxidants combating the ROS?  
Measurements of serum and plasma markers can identify the effectiveness of such 
antioxidant supplements. 
Measures of Oxidative Stress 
Oxidative stress due to ROS assault can be examined by measuring internal 
antioxidant defenses and levels of inflammation.  For example, antioxidant status and uric 
acid levels indicate activity levels of endogenous antioxidant defense systems.  Oxidized 
low-density lipoprotein (oxLDL), C-reactive protein (CRP), isoprostanes, and cytokines 
including interleukins and TNFα are indicators of inflammation and inflammatory 
response mechanisms.  Each of these markers will be further discussed. 
ANTIOXIDANT STATUS    
As briefly discussed, antioxidant status may increase in response to an aerobic 
exercise stimulus, an antioxidant supplement, or a combination of both.  A study 
conducted by Gonzalez-Santiago et al. (2006) demonstrated an increase in antioxidant 
status when the diet of rabbits was supplemented daily with 4 mg of hydroxytyrosol/kg 
body weight.  A group of 8 rabbits was fed an HT supplement along with a standard 
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rabbit diet for one month (group H).  Another group of 8 rabbits was fed an atherogenic 
diet, high in cholesterol and saturated fat, for one month followed by one month of a 
standard rabbit diet and HT supplementation (group AH).  Both groups (H and AH) 
showed a significant increase in total antioxidant capacity using Trolox as a standard 
(TEAC) when compared to the relevant control groups of 8 rabbits each that consumed a 
standard rabbit diet for one month (group C) or two months (group CC), respectively.    
Using an exercise model, Berzosa et al. (2011) found a significant increase in 
plasma TEAC after acute exercise bouts in healthy untrained males.  Thirty-four subjects 
performed three different cycle ergometer exercise protocols in random order with at 
least one week between each test:  VO2max, ride to exhaustion, and a timed submax test.  
In the continuous progressive protocol, maximal oxygen consumption (VO2max) and 
maximal working capacity (MWC) were determined by increasing the workload by 10 
Watts every minute.  The strenuous protocol required subjects to ride until exhaustion at 
VO2max.  Last, the subjects performed a submaximal test at 70% of expected maximum 
for 30 min.  Blood drawn immediately after all three of the cycle ergometer exericise 
protocols exhibited significantly higher total antioxidant values compared to basal level.  
The researchers concluded that a redox-sensitive pathway contributes to the increase in 
enzymatic and non-enzymatic antioxidant defenses after acute exercise.  
On the other hand, Morillas-Ruiz et al. (2006) did not find a significant increase 
in TEAC with exercise nor in combination with an antioxidant supplemented beverage.  
Trained cyclists performed two exercise bouts for 90 minutes at 70% VO2max on different 
occasions separated by one week.  Subjects were randomly assigned to consume 
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throughout the exercise bout 1600 ml of either a placebo beverage or an antioxidant 
supplemented beverage consisting of anthocyanins, flavonols, hydroxycinnamic 
derivatives, stilbenes, and ellagic acid totaling 1253.5 mg antioxidants/L.  There was a 
significant increase in creatine kinase (CK) and lipid oxidation, as measured by 
thiobarbituric acid reactive substances (TBARS), which showed the exercise stimulus to 
be sufficient to elicit muscle damage and oxidative stress; however, there was no 
significant difference in TEAC resulting from exercise or the test beverage consumed.  
The authors of this study concluded that exogenous antioxidants contribute little to 
overall antioxidant status with a good portion of the increase attributed to increased levels 
of uric acid after strenuous aerobic exercise.  
URIC ACID 
Uric acid is a by-product of purine metabolism and is described as a non-
enzymatic antioxidant that may protect against oxidative damage by contributing to 
antioxidant defenses through donation of electrons (Berzosa et al., 2011; Halliwell et al., 
1995; Powers et al., 2004; Powers & Jackson, 2008).  As previously discussed, strenuous 
exercise can increase levels of uric acid.  Mastaloudis et al. (2001) observed this effect in 
trained runners during a 50 km ultramarathon.  Uric acid was measured immediately 
post-race and found to be significantly higher than the pre-race values.  In contrast, 
Quindry and others (2003) found uric acid levels to be significantly lower immediately 
following maximal exercise in healthy, untrained male subjects.   
Similar to total antioxidant status in plasma, uric acid levels have the potential to 
be altered with exogenous antioxidant supplementation.  For example, uric acid was 
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significantly decreased in rabbit plasma after nine-weeks of consumption of a standard 
diet with the addition of 10% extra virgin olive oil or the addition of 10% extra virgin 
olive oil and 7 mg/kg of oleuropein when compared to the control group consuming a 
standard diet.  Researchers concluded that the presence of exogenous antioxidants 
performing similar functions as the endogenous antioxidant defenses decreases the need 
for metabolic production of uric acid (Coni et al., 2000).  Conversely, uric acid values 
were not significantly affected with daily quercetin supplementation over a two-week 
period in healthy, non-exercising individuals (Egert et al., 2008).  Thus, uric acid levels 
and total antioxidant status gives some indication to the viability of internal defenses 
against oxidative stress and inflammation.    
OXIDIZED LOW-DENSITY LIPOPROTEIN (OXLDL) 
A valuable marker of oxidative stress is oxLDL.  High levels of oxLDL have been 
linked to instances of atherogenesis because it is a contributor to the atherogenic process.  
Once LDL particles become oxidized, they become chemo-attractants for monocytes.  
Monocytes and leukocytes enter the arterial intima where the oxidized LDL is engulfed 
by macrophages creating a foam cell.  The foam cells cluster together to form a “fatty 
streak,” an indication of advanced athersclerosis (Patrick & Uzick, 2001).  LDL particles 
that have been oxidized are more atherogenic than ordinary LDL, and inhibition of LDL 
oxidation has been shown to slow the progression of atherosclerotic lesions in the 
endothelium (Manna et al., 1997).  The LDL particle contains internal protection 
mechanisms through lipid composition of the lipoprotein particle and the concentration of 
antioxidants bound to it (Masella et al., 2001).  For example, MUFA consumption 
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produces oleate-rich LDL, which is more resistant to oxidative modification (Ferrara et 
al., 2000).  
In addition to MUFA consumption, dietary antioxidant intake can inhibit LDL 
oxidation by scavenging potentially damaging free radicals, chelation of transitional 
metal ions, and protection of antioxidants within the LDL particle.  Many studies have 
demonstrated a decrease in circulating oxLDL levels, an increase in the number of 
phenolic compounds bound to the LDL particle, and the extent of LDL oxidation when 
consuming olive oil with a higher phenolic content (Covas et al., 2006; EFSA Panel 
2011; Fito et al., 2005; Fitó et al., 2007; Raederstorff, 2009; Rietjens et al., 2007; Tuck & 
Hayball, 2002; Weinbrenner et al., 2004).  In a study by Vazquez-Velasco et al. (2010), 
healthy volunteers between 20 and 45 years of age were randomly assigned to one of two 
treatments for 3 weeks and then crossed over to the other treatment for 3 weeks after a 2 
week washout period.  The treatments consisted of a placebo of 10-15 g/day of sunflower 
oil and the other treatment was the placebo enriched with 45-50 mg/day of HT.  When 
the sunflower oil was combined with HT, oxidized LDL levels were significantly lower 
compared to the sunflower oil.   
As demonstrated with the previous in vivo study, HT is also a powerful inhibitor 
of LDL oxidation in vitro (Aruoma et al., 1998; Aviram & Fuhrman, 1998).  Aruoma and 
colleagues (1998) examined the effects of oxidation on LDL particles when incubated 
with a peroxyl radical and HT.  An EDTA-free LDL solution was incubated with 2,2’-
azobis(2-amidinopropane) hydrochloride (AAPH), a peroxyl radical, and varying 
amounts of HT.  Absorbance at 234 nm was measured over time, using a 
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spectrophotometer, and an inverse dose-response relationship was observed in the 
medium, such that a higher concentration of HT (0 µM, 1 µM, 2.5 µM, 5 µM, and 10 µM) 
exhibited lower levels of peroxyl radical destruction of the LDL particle.  In addition to 
oxLDL, another marker of oxidative stress and inflammation is C-reactive protein. 
C-REACTIVE PROTEIN (CRP) 
CRP is an innate immune system recognition and effector molecule produced in 
the liver as the result of an acute-phase response and can increase from less than 1 µg/ml 
to as high as 1,000 µg/ml.  CRP synthesis is stimulated by inflammatory cytokines, such 
as TNFα, IL-6 and IL-1 and circulating levels of CRP typically correlate with IL-6 levels, 
both markers indiciative of inflammation (Du Clos & Mold, 2004; Vincent & Taylor, 
2006). 
More importantly, circulating levels of CRP are closely linked with disease risk.  
Elevated CRP levels are related to increased risk of death associated with coronary heart 
disease, coronary artery disease, and myocardial infarction in patients with angina 
pectoris (Patrick & Uzick, 2001).  Participants in the Women’s Health Study were 4.4 
times more likely to suffer a cardiovascular event in the highest quartile of high 
sensitivity CRP (hs-CRP), which was the most sensitive marker of cardiovascular events 
in this study.  As such, participants in the highest quintile of both hs-CRP and the ratio of 
total cholesterol to HDL exhibited an 8.7 fold increased risk for a cardiac event (Patrick 
& Uzick, 2001). 
CRP levels may be attenuated with regular exercise or antioxidant supplements.  
For instance, participants with a higher risk ratio of myocardial infarction assigned to a 
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six-month individualized, supervised exercise program were evaluated for CRP levels 
before and after the treatment period.  Although not significant, there was a 35% decrease 
in serum CRP levels after training.  The authors did find, however, a signficant decrease 
in atherogenic cytokines and a significant increase in atheroprotective cytokines 
suggesting that long-term exercise decreases atherogenic activity of blood mononuclear 
cells and protection against ischemic heart disease (Smith et al., 1999).  Furthermore, Fito 
et al. (2008) observed a significant decrease in CRP after chronic consumption of virgin 
olive oil.  Stable coronary heart disease patients were initially randomized to one of two 
treatments:  50 ml of virgin olive oil or 50 ml of refined olive oil daily for three weeks, 
and then crossed-over to the other group after a 2 week washout period.  Compared to 
refined olive oil consumption, both CRP and IL-6 levels were significantly decreased 
after 3 weeks of consuming virgin olive oil.  The authors concluded that virgin olive oil 
consumption could provide beneficial effects by lowering markers of inflammation in 
this population. 
ISOPROSTANES 
F2-isoprostanes are another marker of oxidative stress, as they are a reliable 
indicator of lipid peroxidation (Mastaloudis et al., 2001; Raederstorff, 2009; Vincent & 
Taylor, 2006).  A reduction in excreted isoprostanes is evidence of decreased lipid 
peroxidation in healthy humans (Schwedhelm et al., 2003).  An inverse dose-response 
relationship exists between the rate of excretion of an isoprostane, specifically 8-iso-
PGF2a, and amounts of phenolics, or HT, ingested (Cornwell & Ma, 2008; Covas, 2007; 
(Tuck & Hayball, 2002; Visioli et al., 2000; Visioli et al., 2001).  On the contrary, Leger 
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et al. (2005) did not see a significant variation in 8-iso-PGF2a urinary exretion during 
four-days of HT supplementation.  The dose of HT administered during this protocol is 
typical of a southern European diet and approximately equivalent to consuming 15 olives 
on the first day followed by consumption of 7-8 olives per day for the remaining three 
days.  The subjects in this study were Type I diabetics whose basal 8-iso-PGF2a levels 
were already elevated three-fold; therefore, the authors attributed the lack of a significant 
decrease in isoprostane excretion to the elevated basal levels.   
 F2-isoprostane excretion can also be the result of an acute exercise stimulus.  For 
example, Mastaloudis et al. (2001) observed a significant increase in F2-isoprostane 
excretion after strenuous exercise.  F2-isoprostane levels of 11 trained endurance runners 
were measured before a 50 km ultramarathon and immediately after the race.  The levels 
of F2-isoprostane increased significantly from pre-race to post-race when compared to a 
sedentary protocol one month later, suggesting that extreme endurance exercise increases 
lipid peroxidation and F2-isoprostanes.  The increased oxidative stress due to exercise can 
also be exhibited by release of various cytokines as described below. 
CYTOKINES 
Cytokines are potent intercellular signaling molecules that modulate inflammatory 
and immune responses (Nieman et al., 2005).  During the acute phase response, levels of 
TNFα, IL-6, and IL-1 are increased, and consistent elevation of these cytokines is 
strongly correlated with risk of primary and subsequent myocardial infarction and death 
(Patrick & Uzick, 2001).  As previously discussed, CRP production is modulated by 
77 
TNFα, IL-6, and IL-1; however, IL-10, an anti-inflammatory cytokine, is stimulated by 
CRP (Du Clos & Mold, 2004).  
In healthy subjects, acute exercise increases the plasma concentrations of  pro-
inflammatory cytokines, specifically TNFα and IL-1β; however, a significant increase in 
these inflammatory markers may be attenuated by the release of anti-inflammatory 
cytokines: IL-10, and interleukin-one receptor antagonist (IL-1ra) (Baydur et al., 2010; 
Nieman et al., 2001).  Muscle contractions during aerobic exercise release and 
significantly increase IL-6 levels, and this increase in IL-6 can suppress the production of 
TNFα during an acute bout of exercise (Gleeson, 2007; Teixeira et al., 2009).  Suzuki et 
al. (2000) showed the effects of exercise on circulating cytokine levels.  IL-1ra and IL-6, 
both negative feedback inhibitors of cytokine production, and IL-10, an inhibitory 
cytokine, all significantly increased during a marathon race in trained endurance runners.  
Nieman and others (2005) observed similar findings in trained runners after a 160 km 
race. 
 Antioxidant supplementation during exercise causes equivocal results in 
downgrading cytokine expression related to exercise.  For example, increases in 
inflammatory cytokines, IL-1β, IL-6, and TNFα, were observed after a baseline exercise 
test consisting of 45 min of aerobic exercise at 70% VO2max on a cycle ergometer in six, 
healthy untrained males.  Post exercise values were significantly attenuated after 1 month 
of chronic consumption of an antioxidant supplement consisting of vitamins A, C, and E, 
allopurinol, and N-acetylcysteine (Vassilakopoulos et al., 2003).   
78 
On the other hand, a study conducted by Teixeira et al. (2009) found no reduction 
in IL-6 levels after 4 weeks of antioxidant supplementation.  Trained kayakers performed 
a baseline 1000 m simulated kayak race and were then randomly assigned to either a 
placebo or antioxidant supplement consisting of α-tocopherol, vitamin C, β-carotene, 
lutein, selenium, zinc, and magnesium for four weeks.  After 4 weeks of consumption, 
the kayakers would then perform  the same exercise protocol.  Measurements of IL-6 
were taken at rest before commencement of the exercise and 15-minutes after the 
simulated kayak race at both exercise trials.  IL-6 increased significantly from rest to 
post-race regardless of treatment.  The authors concluded that this antioxidant cocktail 
did not offer protection against exercise-induced inflammation as measured by IL-6. 
Summary 
 The lower incidences of cardiovascular disease and cancer associated with the 
Mediterranean diet have motivated researchers to investigate its essential benefits.  Many 
have found that olive oil, the main source of fat in this diet, is an important contributor to 
the decreased disease risk.  First, olive oil contains a high concentration of 
monounsaturated fatty acids, which exhibit greater protective properties against free 
radical damage compared to polyunsaturated fatty acids.  Second, olive oil contains a 
high amount of phenolic antioxidants.  Of the three main phenols in olive oil, 
hydroxytyrosol is more abundant and more powerful because of its high ROS scavenging 
capability.  Many researchers have demonstrated reduced inflammatory markers and thus, 
a decreased disease risk with chronic consumption of hydroxytyrosol. 
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 Researchers have also investigated the effects of antioxidants, and HT 
specifically, on aerobic exercise-induced oxidative stress.  The high-energy demand 
required by exercise causes the release of many ROS, which harm surrounding cells and 
tissues.  However, adaptation to exercise increases the endogenous antioxidant systems to 
combat ROS released from the mitochondria.  The results of many studies examining 
antioxidant consumption in conjunction with aerobic exercise remain inconsistent 
regarding performance, antioxidant status, and inflammation.  At the present time, further 
research is necessary to elucidate the effects of HT on the specific markers of oxidative 
stress and inflammation associated with aerobic exercise.    
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APPENDIX A - INFORMED CONSENT TO PARTICIPATE IN 
RESEARCH 
Informed Consent to Participate in Research 
The University of Texas at Austin 
IRB #2009-09-0101 
You are being asked to participate in a research study. This form provides you with 
information about the study. The Principal Investigator (PI, the person in charge of this 
research) or his/her representative will provide you with a signed and dated copy of this 
form to keep for your reference, and will also describe this study to you and answer all of 
your questions. Please read the information below and ask questions about anything you 
don’t understand before deciding whether or not to take part. Your participation is 
entirely voluntary and you can refuse to participate or discontinue participation without 
penalty or loss of benefits to which you are otherwise entitled.  It is important that you be 
completely truthful with the PI and study staff regarding your health history so that you 
do not harm yourself by participating in the study. 
 
Title of Research Study: 
Effects of water-soluble olive extract supplementation on antioxidant status, exercise 
performance, muscle metabolism, muscle damage and inflammation 
 
Principal Investigator(s) (include faculty sponsor), UT affiliation, and Telephone 
Number(s):  
John Ivy, Ph.D., Principal Investigator, Department Chair of Kinesiology and Health 
Education, 512-471-8599  
Lynne Kammer, Co-investigator, Research Assistant, Department of Kinesiology and 
Health Education, 512-471-8601 
Zhenping Ding, Co-investigator, Research Engineer, Department of Kinesiology and 
Health Education, 512-471-8601 
Mark Hutchens, M.D., Co-investigator, Physician, 512-473-0201 
 
Funding source (Sponsor):   
DSM Nutritional Products (Kaiseraugst, Switzerland)  
What is the purpose of this study?   
The purpose of the proposed study is to compare the effect of two different doses of an 
investigational olive extract versus a placebo on exercise performance, muscle 
metabolism, muscle damage, antioxidant status and inflammation.  An investigational 
olive extract means that it is experimental and not currently marketed for sale.  About 60 
people will be participating in this study. 
 
What will be done if you take part in this research study?   
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After the Screening Visit, participation in this research study includes 12 study visits (1 
Familiarization Visit, 2 Muscle Biopsy Visits, 2 Blood Draw Visits and 7 Exercise Visits) 
and one Exit phone call that will occur over 9 weeks.  You will also be contacted during 
the study with reminder emails. The visits are scheduled in advance and must not be 
changed.  If you become sick or have schedule conflicts, we may not be able to 
accommodate the schedule change while maintaining the protocol test cycles. 
 You will be randomly assigned one of three supplements:  50mg olive extract, 
150mg of olive extract or a placebo that you will consume daily for 6 weeks of the study. 
You have an equal chance of being assigned to a particular supplement. You will also 
complete a daily online survey that will take approximately 5 minutes per day.  The study 
will require about 25 hours of your time to complete over 9 weeks.  Approximately 60 
people from this site will participate in this study.  
 During the study we will ask you to limit your intake of wine to no more than 2 
glasses per week, and coffee and tea to no more than 1 cup per day. We will also provide a 
list of foods for you to avoid during the 24 hours prior to your Exercise visits (coffee, tea, 
chocolate, wine, cherry tomatoes, broccoli, blueberries and onions). 
 We will give you instructions to prepare for each visit to our lab and will send 
reminder emails to you. Depending on the visit, you must fast (only water) for 2-12 hours. 
If these instructions are not followed and we cannot reschedule you, you will be excused 
from the study.    
A summary of the tasks by week is in Table 1 and described below: 
Familiarization Visit (2-hour fast, 1-hour duration).  We will familiarize you with the 
cycling ergometer and practice breathing into the mouthpiece for the monitoring of 
oxygen consumption and carbon dioxide emission. We will draw 4ml of blood to send to 
a lab to verify that you do not have Hepatitis B or C. This practice ride will be shorter 
than the actual test ride and will take approximately 30 minutes to complete.   The results 
from your Hepatitis B/C test will be available prior to your first Muscle Biopsy Visit.  If 
the test is positive, you will be notified by the study physician to consult with your 
physician to determine the appropriate course of treatment action, and excused from the 
study. 
Muscle Biopsy Visit (12-hour fast, 1-hour duration).  We will perform biopsies at the 
start and end of the project.  Prior to the visit, you will fast for 12 hours (water only) and 
shave both of your thighs all of the way around your leg.  
After you arrive in the lab, 15ml (about 1 tablespoon) of blood will be drawn from 
a forearm vein.  The blood samples will be analyzed for markers of immune system 
function, muscle damage and general health. 
After the blood draw, biopsies (100 mg total - about the size of 4 grains of rice) 
will be taken by John Ivy, Ph.D. from the vastus lateralis, a thigh muscle. This biopsy 
procedure will involve first cleaning the skin where the incision will be made and then 
anesthetizing or eliminating sensation in a two-inch square area on the thigh by injecting 
a medication (Lidocaine) into the skin using a needle. Next, a 5-8 mm (0.25 - 0.33 inch) 
incision will be made in the skin and fat below the skin, so that a special needle can be 
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inserted into the thigh muscle and remove a small piece of muscle.  The incision will be 
closed with a butterfly bandage and covered with multiple layers of gauze covered tightly 
with tape.  We will provide instructions to you to take care of the incision.    
Your muscle tissue will be used to analyze changes that may affect your ability to 
process oxygen during exercise.  A portion of it will be sent to the sponsor (DSM 
Nutritional Products) to determine the effect of the olive product on the gene expression 
profile involved in the energy metabolism.  The sponsor or the investigator will not be 
performing genetic finger printing and will destroy any remaining tissue after their testing 
has been completed. 
Following the muscle biopsy, we will perform a Dual Energy X-Ray 
Absorptiometry (DEXA) scan to measure your body composition – specifically, your 
amount of body fat and lean tissue.  During the DEXA scan you will wear clothing that 
does not contain metal, such as workout shorts and a t-shirt, and lie on a padded table.  
The DEXA machine is not enclosed like an MRI machine.   
VO2MAX and Lactate Threshold (LT) Visit (2-hour fast, 1½-hour duration). We will 
initially perform a lactate threshold test then a VO2MAX on the bicycle ergometer. You 
will breathe continuously through a mouthpiece so that we can collect information about 
your oxygen consumption. The LT test is not exhausting and will consist of a series of 5 
min stages for at least 5-6 stages until an increase in baseline blood lactate level is 
observed. Blood lactate will be measured by a finger prick during the last minute of each 
stage. Upon completion of the LT test, you will have a 5-minute break where you can 
drink water, then you will perform a VO2MAX. 
During the VO2MAX test, a computer will increase the exercise intensity until muscle 
fatigue and exhaustion.  This test will last approximately 25 minutes and physically stress 
and challenge you for about 5 minutes at the end of the test. 
Steady-State ride with Time Trial (SS-TT) (10-hour fast, 2-hour duration). When you 
arrive at the lab, we will weigh you, then insert a catheter fitted with a three-way 
stopcock under sterile conditions, into a forearm vein, then add a catheter-extension, and 
tape it into place.  This will be performed under John Ivy, Ph.D., an exercise physiologist.  
Ten milliliters of blood will then be drawn.   We will draw blood 2 additional times 
during your ride for a total of 27ml, or about 2 tablespoons, of blood.  You should be 
riding for 1-1.25 hours total time. At the end of the SS-TT test, we will provide a light 
snack and beverage to you. 
Blood Draw.  This visit will take approximately 30 minutes. We will draw 15ml of blood 
from a forearm vein and perform safety blood analyses at weeks 2, 4 and 6 to compare 
against your baseline blood sample collected at the first Biopsy Visit.  The lab results will 
be available within 48 hours.  If the study physician decides that changes in your blood 
results are due to the study product, we will contact you and ask you to stop consuming 
the study product.  If you have missed more than one dose per week of the Study Product 
or do not take the Study Product in the morning, you will be excused from the study. 
Food and Medication Logs (FM Logs). We will provide you with Food and Medication 
Logs to record food, drinks, supplements and medication for the days immediately prior 
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to your Biopsy and Exercise visits. You will be instructed to write down everything in 
pen on the Food Log that you eat and drink, and any medications and dietary supplements 
on the Medication Log.  You will bring your food logs to your Biopsy and Exercise 
Visits.  We will make copies of your logs and return them to you to help you maintain a 
consistent diet before your Biopsy and Exercise Visits. 
Study Product (SP). You will be randomly assigned one of three supplements (50mg 
olive extract, 150mg olive extract or placebo).  Each supplement consists of 3 similar-
appearing capsules per dose.  We will not know which supplement you are receiving.   
We will provide 2 weeks of Study Product to you.  Each day you will push all 3 capsules 
from a blister and take with water when you eat your breakfast.  You must take all 3 
capsules in the morning.  If you miss a dose, do not double the dose or take it in the 
afternoon.    If you miss more than 1 dose per week of the study, you will be excused 
from the study.  If you travel, you must take the Study Product with you to avoid missing 
a dose.  Each time that you come into the lab, you must bring the empty and partially 
empty packages of Study Product with you; do not throw them out. 
 
 
Table 1.  Example schedule for this study protocol (continued on next page) 
 
SP = Study Product Log = Online Log 
SS-TT = Steady-State/Time-Trial ride LT/VO2MAX  = Lactate Threshold and VO2MAX Tests 
FM Log = Food/Medication Logs Fast = no food, coffee, tea or other drinks; only water 
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   Blood (12 hr fast)    6  Lab 
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The Project Duration is: January 2010 to December 2010.  It will require 25 hours of 
your time to complete the study.  
 
What are the possible discomforts and risks? 
The investigators have made every effort to keep the risks and discomforts to a minimum.  
You will be carefully screened at the beginning of this study to see if you can participate 
safely; however, participation in this study involves some risk.   
Muscle Biopsies: Biopsies will be taken by John Ivy, Ph.D., from the vastus lateralis, a 
quadriceps muscle. You may experience mild discomfort at the site of the incision and 
biopsy. There may be slight bruising to the skin and the muscle. In approximately one out 
of every five cases, a general soreness may persist for 2 to 3 days, but this does not inhibit 
function. In very rare cases, you may experience severe pain. There is a small possibility (1 
in 1,300) that the feeling in the biopsy area will be temporarily lost for 2 to 3 months due to 
damage to the sensory nerves. There is also a possibility of infection, but this can be 
remedied with the appropriate antibiotics. There are no alternative methods for obtaining 
muscle samples which are both useful for this study and reduce potential risk. The chance 
of infection will be minimized by adhering to sterile procedures. The investigators will 
examine biopsy sites the following day prior to the LT/VO2MAX test. 
Blood Draws:  In this study a trained technician will obtain a 15-27ml (about 1-3 
tablespoons) sample of your blood during each visit that will be analyzed to measure 
markers of immune system function, muscle damage and general health or metabolism. 
Blood samples will be obtained by finger-stick, venipuncture and catheterization. A finger-
stick at the tip of a finger is routinely used to obtain a small amount of blood for lactate 
testing.  It may be accompanied by minor discomfort, and there is a possibility of infection.  
Venipuncture involves inserting a needle into a vein in the arm and withdrawing a sample 
of blood. It is routinely used to obtain blood for physical examinations. Venipuncture is 
accompanied by minor discomfort at the site of the needle entry and may result in slight 
bruising and a feeling of faintness. Venipuncture will be used during the Biopsy and Blood 
Draw Visits.  Catheterization of a vein is a routine and preferable procedure for obtaining 
multiple blood samples because it requires the skin to be pierced only once, since the 
catheter is left in the vein. Catherization will be used during the Exercise Visits.  Some 
participants may feel faint during catheterization and blood draws. There is the possibility 
of an infection with catheterization. There are no alternative methods to obtaining blood 
samples that are both useful to this study and reduce the possible risks.  
VO2MAX tests:  Near the end of your VO2MAX tests you should feel fatigued and this feeling 
may last approximately 15 to 20 minutes after the test. You may also feel some stomach 
discomfort and lightheadedness. However, the likelihood of this is rather remote since you 
are physically active and normally participate in aerobic exercise.  
Steady-State Time-Trial tests:  Since you will perform the tests after a 10-hour overnight 
fast, you may experience symptoms of low blood sugar, or hypoglycemia. These symptoms 
may include dryness in your mouth, dizziness, feeling faint and disorientation. Performing 
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the tests after an overnight fast is the best way for us to isolate the effects of our 
supplement. 
DEXA Scans:  DEXA scans produce an amount of radiation of 0.02-0.05 mRem, which is 
similar to 1/10 of a chest x-ray.  There is no immediate short-term or long-term risk to adult 
humans from exposure to this radiation dose. All DEXA scans will be performed by a 
certified technician. 
The intervention being studied involves ingesting an investigational olive product. The 
olive product is a natural product as it is a water-soluble olive extract derived from olive 
processing. This kind of product has been given to other persons in a lower concentration 
and has been tested at significantly higher doses in rodents.  The investigational product 
has been tested in a complete safety package required to test products in human studies. 
The maximum dose in this study has been safety approved by several safety studies. 
Health risks related with the intake are not known but not expected. We will carefully 
monitor your health status during the study. 
In addition, we ask that you please consider the 9-week time commitment for this study. 
You should consider the impact of this on your work, academic and personal 
commitments before you decide to volunteer as a subject for this study. 
There may be risks from participating in this study that are unknown.  Any new important 
information, which is discovered during the study that may affect your decision to stay in 
the study, will be given to you.  If you wish to discuss the information above or any other 
risks you may experience, you may ask questions now or call the Principal Investigator 
listed on the front page of this form.  
What are the possible benefits to you or to others?  
There may be no direct medical benefit for participation; however, you will receive 
information regarding your diet, BMI, fitness level, body composition and blood chemistry 
results.   You will also receive information on the general outcome of the study upon 
completion of the analysis. 
 The study will provide a better understanding of the effects of an investigational 
olive extract that may help other healthy adults obtain better fitness and reduced 
inflammation through supplementation. 
 
If you choose to take part in this study, will it cost you anything?  
No, it will not cost you anything to participate in the study, and you should not incur 
additional expenses to participate in this study. 
 
Will you receive compensation for your participation in this study?   
Yes, to pay you for your time and travel involved with participating in this study, you 
will receive a total of $500 upon completion of all study visits and formally exiting the 
study.  You will also receive your data along with an explanation of the results.  Partial 
compensation will be based on completion of the Biopsy and Exercise phases:  
 
$75 for baseline 3-day testing (biopsy, VO2 max/lactate threshold, time trial ride) 
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$75 for mid point testing at 3 weeks (VO2 max/lactate threshold, time trial ride) 
$75 for final 6 week testing (same as baseline) 
$275 after exit 
 
At the end of the study we will call you to ask questions about how you feel and if you 
have experienced any health problems.  Once we have spoken to you about the study exit, 
we will process your payment for $500. 
 If you complete part of the Biopsy and/or Exercise Visits, you will receive 
compensation based on your last completed Test Session. You will not receive 
compensation if you only complete the Screening Visit and Familiarization Visit.   
Payment will be made to you at the end of the study.  You will be responsible for any taxes 
assessed on your compensation. 
 
What if you are injured because of the study?   
In the event of a study related injury, please contact the Principal Investigator.  The 
University has no program or plan to provide treatment for research-related injury or 
payment in the event of a medical problem. The University also has no program or plan for 
continuing medical care and/or hospitalization for research-related injuries or for financial 
compensation.  However, if injuries occur as a result of study activity, DSM Nutritional 
Products agrees to pay medical expenses necessary to treat the injury, if you have 
followed the directions of the study doctor and to the extent you are not otherwise 
reimbursed by medical insurance.  To receive this medical expense reimbursement from 
DSM Nutritional Products, you may be asked to provide a copy of your medical records 
related to this injury and/or be examined a physician selected by DSM Nutritional 
Products.  No other compensation will be provided beyond that which is listed in this 
informed consent.  You will not lose any of your legal rights as a research subject by 
signing this consent document. 
 If there is a serious adverse event during the study and you are admitted to a 
hospital, you agree to provide a copy of your Discharge Summary to the 
Principal Investigator and talk to the Study Physician to answer questions specific to your 
adverse event. 
 
If you do not want to take part in this study, what other options are available to you?  
Your participation in this study is entirely voluntary. You are free to refuse to be in the 
study, and your refusal will not influence current or future relationships with The 
University of Texas at Austin. 
How can you withdraw from this research study and who should you call if you 
have questions? 
You may leave the study at any time for any reason; however, you may be asked to 
complete certain procedures, for example cooling down after exercise, since withdrawing 
during these procedures may present safety concerns.   
Anticipated circumstances under which participation may be terminated by the 
investigator without the participant’s consent. These include: 
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1. The study doctor thinks it is necessary for your health and safety. 
2. You have not followed study instructions: 
a. Diet Management.    You eat foods or consume beverages in excess of the 
study requirements. 
b. Inconsistent pre-study exercise and/or diet.  To control our experimental 
conditions, it is critical that your diet is similar for 48 hours and you do not 
participate in strenuous exercise before Biopsy and Exercise Visits. 
Changing your diet and exercise pattern during the days leading up to the 
Biopsy and Exercise Visits will affect the study results. 
c. Medications. You begin taking an excluded medication. 
d. Supplements.  You begin taking an excluded supplement. 
e. Study Product.  You do not take complete daily doses during the required 
timeframe or miss more than one dose per week. 
f. Online Log.  You do not fill out the daily survey to record your Study 
Product intake and health status.  
 
3. If you are unable to attend scheduled appointments, do not fast prior to Biopsy 
and Exercise Visits, do not consume Ensure prior to SS-TT Tests or cannot 
complete the study within the required time.  
4. The Sponsor has stopped the study. 
5. You no longer meet the qualification requirements. 
 
If you wish to stop your participation in this research study for any reason, you 
should contact the Principal Investigator: John Ivy, Ph.D. at 512-471-8599. You 
should also call the Principal Investigator for any questions, concerns, or complaints 
about the research. You are free to withdraw your consent and stop participation in 
this research study at any time without penalty or loss of benefits for which you may 
be entitled. Throughout the study, the researchers will notify you of new information 
that may become available and that might affect your decision to remain in the study.  
If you would like to obtain information about the research study, have 
questions, concerns, complaints or wish to discuss problems about a research study 
with someone unaffiliated with the study, please contact the IRB Office at (512) 471-
8871 or Jody Jensen, Ph.D., Chair, The University of Texas at Austin Institutional 
Review Board for the Protection of Human Subjects at (512) 232-2685.  Anonymity, if 
desired, will be protected to the extent possible. As an alternative method of contact, 
and email may be sent to orsc@uts.cc.utexas.edu or a letter sent to IRB Administrator, 
P.O. Box 7426, Mail Code A3200, Austin, TX 78713. 
 
AUTHORIZATION TO USE AND DISCLOSE INFORMATION FOR 
RESEARCH PURPOSES 
Federal regulations give you certain rights related to your health information.  These 
include the right to know who will be able to get the information and why they may be 
able to get it.  The Principal Investigator must get your authorization (permission) to use 
or give out any health information that might identify you. 
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How will your privacy and the confidentiality of your research records be protected? 
Authorized persons from the University of Texas at Austin, the Institutional Review Board, 
the Sponsor and its delegates and regulatory authorities have the legal right to review your 
personal health information and the research records collected in this study for the purposes 
of collecting data, verifying that the data is correct and checking that the study is conducted 
properly. This information will be used for clinical research and also for seeking approval 
from domestic and/or foreign regulatory authorities to market the experimental olive 
extract. 
 This research project is sponsored by DSM Nutritional Products (Kaiseraugst, 
Switzerland). “Sponsor” includes any persons or companies that are working for or with 
the sponsor, or are owned by the sponsor.  This sponsoring agency also has the legal right 
to review your research records. 
All data collected will be stored using a code (subject number and initials). It will 
not be stored by your name; however, during the study, a list will be maintained, linking 
your code and name. The contact information, master key list, and other materials 
containing names will be separated from the results and kept in a locked file cabinet. 
Your health questionnaire will also be kept confidential and stored in a locked office in 
the Exercise Physiology & Metabolism Laboratory in Bellmont 818. The list and the 
health questionnaire will be physically destroyed when the sponsor notifies the 
investigator that the data no longer needs to be retained.  Only principal researchers have 
access to the file, but representatives of the Sponsor may review the files during the 
study.  We will be collecting your name, phone number, and address for contact, 
scheduling and payment purposes only. If you have not previously been paid by The 
University of Texas at Austin, we will also collect your social security number for 
payment purposes only.  This information will be kept secured and will be physically 
destroyed after you are paid. If you become ineligible to participate at any point during 
the study, the data collected thus far will be kept confidential and stored in a locked file 
cabinet until we finish data collection for this study. 
If in the unlikely event it becomes necessary for the Institutional Review 
Board to review your research records, then The University of Texas at Austin will 
protect the confidentiality of those records to the extend permitted by law. Your 
research records will not be released without your consent unless required by law or a 
court order. The data resulting from your participation may be made available to 
other researchers in the future for research purposes not detailed within this 
consent form. In these cases, the data will contain no identifying information that 
could associate you with it, or with your participation in any study.   
If the results of this research are published or presented at scientific meetings, your 
identity will not be disclosed.   
 
What if I decide not to give permission to use and give out my health information? 
By signing this consent form, you are giving permission to use and give out the health 
information listed above for the purposes described above.  If you refuse to give 
permission, you will not be able to participate in this research study. 
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May I review or copy the information obtained from me or created about me? 
You have the right to review and copy your health information.  If you decide to 
participate in this study and sign this permission form, you will not be allowed to look at 
or copy your study information until after the research is completed. 
 
May I withdraw or revoke (cancel) my permission? 
Yes, you may withdraw or take away your permission to use and disclose your health 
information at any time.  You do this by sending written notice to the Principal 
Investigator.  If you withdraw your permission, you will not be able to continue being in 
this study. 
When you withdraw your permission, no new health information, which might 
identify you, will be gathered after that date.  Information that has already been gathered 
may still be used.  This would be done if it were necessary for the research to be reliable. 
 
Is my health information protected after it has been given to others? 
If you give permission to give your identifiable health information to a person or 
business, the information may no longer be protected.  There is a risk that your 
information will be released to others without your permission.  However, DSM Nutrition 
Products will take reasonable measures to prevent the unauthorized disclosure of your 
individually identifiable health information. Information that is collected for research 
purposes continues to be analyzed for many years; however, blood and muscle tissue 
specimens will be destroyed after lab analysis has been completed. This authorization 
will expire in 10 years, or the date when data and specimens will be destroyed or retained 
without identifiers, whichever is earlier. 
A new Federal law, called the Genetic Information Nondiscrimination Act (GINA), 
generally makes it illegal for health insurance companies, group health plans, and most 
employers to discriminate against you based on your genetic information. This law 
generally will protect you in the following ways: 
• Health insurance companies and group health plans may not request your genetic 
information that we get from this research 
• Health insurance companies and group health plans may not use your genetic 
information when making decisions regarding your eligibility or premiums. 
• Employers with 15 or more employees may not use your genetic information that 
we get from this research when making a decision to hire, promote, or fire you or 
when setting the terms of your employment.  
All health insurance companies and group health plans must follow this law by May 22, 
2009. All employers with 15 or more employees must follow this law as of November 21, 
2009. 
 
Be aware that this new Federal law does not protect you against genetic discrimination by 
companies that sell life insurance, disability insurance, or long-term care insurance, nor 
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does it prohibit discrimination on the basis of a genetic disease or disorder that you 
already know about. 
 
By signing the consent form, you acknowledge that you have voluntarily donated your 
blood and muscle tissue specimens to The University of Texas at Austin for research 
purposes. The University has no plans to compensate you for any commercial uses of the 
products that may be derived from the specimen. The University of Texas at Austin will 
maintain ownership of the specimen. 
 
Will the researchers benefit from your participation in this study?  
The researchers are being paid by DSM Nutrition Products to conduct this study.  
Otherwise, they will not benefit from this study beyond publishing or presenting the 
results. 
 
Consent to test your blood for HIV and other diseases 
If an investigator is exposed to your blood sample through an inadvertent needle stick or 
during biochemical analysis, you grant permission to have your blood tested for HIV and 
other blood-borne diseases. If a positive test is found, you will be informed by the 
Principal Investigator of the study (John Ivy, Ph.D.) of the results in a private setting. 
 
92 
Please review the risks listed in the following table and initial and date each.   
 Risk Initials Date 
1 I understand that by participating in this study, any data collected 
about me including personal and health information will be stored 
using a subject number and my initials. 
  
2 I understand that by participating in this study, I will provide blood 
and tissue specimens that will become the property of The 
University of Texas at Austin. 
  
3 I understand that by participating in this study, some of my blood 
and tissue specimens will be sent to the sponsor company, DSM 
Nutritional Products. 
  
4 I understand that by participating in this study, there is a chance that 
my individually identifiable health information may be obtained 
from my blood and tissue specimens. 
  
5 I understand that by participating in this study, my health 
information will be used for investigational purposes only and not 




6 I understand that by participating in this study, my personal 
information, including my social security number if it is not already 
in The University of Texas at Austin payment system, will be 
collected so that I may be compensated for my participation as 
described in this Informed Consent Form.  This personal 




7 I understand that by participating in this study, my blood and tissue 
specimens, and any data collected about me will be saved for a 






As a representative of this study, I have explained the purpose, the procedures, the 
benefits, and the risks that are involved in this research study: 
 
             
Signature and printed name of person obtaining consent   Date 
 
 
You have been informed about this study’s purpose, procedures, possible benefits and 
risks, and you have received a copy of this form. You have been given the opportunity 
to ask questions before you sign, and you have been told that you can ask other 
questions at any time. You voluntarily agree to participate in this study.  By signing 
this form, you are not waiving any of your legal rights. 
 
 
             
Printed Name of Subject        Date 
 
 
             
Signature of Subject   Date 
 
 
             
Signature of Principal Investigator   Date 
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___________/ __________ / ___________  

















 Black/African American 
 American Indian/Alaskan Native 
 Asian  






 Exercise & Duration Intensity 
(L/M/H) 
Mon   
Tues   
Wed   
Thurs   
Fri   
Sat   
Please describe your regular 
physical activity during a 
typical week.  Please include 
the type of activity, duration 
and intensity.   
 
For intensity use:  
Low:  My heart rate did not 
rise very much, I did not sweat 
or sweated very little 
Medium:  My heart rate rose 
somewhat, but I was able to 
talk easily 
High:  My heart rate was very 
high and I was unable to carry 
on a conversation 
 
Sun   
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Answer the questions below by checking the appropriate box. 
Yes No   
  1.  Has your doctor ever said that you have a heart condition and that you should 
only do physical activity recommended by a doctor? 
  2. Do you feel pain in your chest when you do physical activity? 
  3. In the past month have you had chest pain when you were not doing physical 
activity?         
  4. Have you ever lost your balance because of dizziness or have you ever had a 
loss of consciousness? If yes explain: ____________________________________________________  
  5. Have you ever had racing of your heart or skipped heartbeats? 
  6. Has any family member or relative died of heart problems or sudden death 
before the age of 50? 
  7. Have you been told you have high blood pressure? 
  8. Have you been told you have a heart murmur? 
  9. Have you been told that you have kidney disease? 
  10. Have you been told that you have Type 1 or Type 2 diabetes? 
  11. Have you received an organ transplant? 
  12. Have you had or do you currently have a malignancy (cancer)? 
  13. Have you had a severe viral infection within the past month? 
  14. Have you been told that you have a chronic contagious, infectious disease such 
as tuberculosis, hepatitis B, hepatitis C or HIV? 
  15. Are you taking any performance enhancing drugs or supplements other than a 
multivitamin.  If so, what?  
___________________________________________________________________________________________   
  16. Do you have any medical problems or illnesses such as osteoporosis, diabetes, 
kidney or liver disease, a chronic contagious or infectious disease? If yes, please 
describe: 
___________________________________________________________________________________________    
  17. Are you currently on any regular medication including non-prescription 
medications?   If your answer is “yes,” please list your regular medication(s) 
and how long you have been taking it (them): 
___________________________________________________________________________________________   
___________________________________________________________________________________________   
  18. Are you currently in another study? 
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Yes No   
  19. Do you have any known allergies? If yes please specify:   
___________________________________________________________________________________________  
  20. Approximately how much olive oil to you consume per day?   
___________________________________________________________________________________________   
  21. Approximately how much chocolate do you consume per day?   
___________________________________________________________________________________________   
  22. Do you smoke? 
  23. When was the last time you had a physical? ________________________________________________________  
 
             
Signature       Date 
 
97 
APPENDIX C – SAMPLE FOOD LOG 
MEAL Amount Brand Food 
   
   
   
   
   
   
Breakfast 
   
   
   
   
   
   
   
Lunch 
   
   
   
   
   
   
   
Dinner 
   
   
   Snacks 
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APPENDIX D – DATA 




TEAC (mM) Raw Data – PLA (n=19) 
 
 
pre end pre end pre end pre end
102 0.47 0.45 0.59 0.42 0.53 0.46 0.47 0.49
106 1.14 0.95 1.12 0.78 1.08 1.20 1.32 1.09
107 0.87 0.79 0.94 0.88 0.72 0.67 0.80 0.86
110 1.21 1.23 1.29 1.48 1.22 1.44 1.35 1.13
113 1.01 1.08 1.03 1.04 0.99 1.15 0.99 0.99
117 0.79 1.21 0.84 0.75 0.72 0.83 0.76 0.73
120 1.35 1.16 1.34 1.18 1.28 1.35 1.08 1.24
125 0.94 1.09 1.32 1.21 0.88 1.22 1.22 1.25
126 1.20 1.06 1.18 1.23 1.00 1.25 1.30 1.20
139 0.95 1.10 1.02 0.89 0.82 1.00 1.03 0.93
141 1.34 1.28 1.29 1.19 1.25 1.14 1.40 1.19
147 1.03 1.14 --- --- 0.91 1.08 1.06 1.02
148 0.87 0.73 0.78 0.79 0.94 1.10 0.80 0.86
149 1.60 1.51 1.47 1.28 1.26 1.18 1.61 1.48
153 1.03 1.16 1.08 1.13 0.84 0.94 0.63 1.12
157 0.84 0.94 1.06 1.38 0.69 0.70 0.84 0.77
160 0.51 0.47 0.40 0.42 0.37 0.42 0.49 0.45
161 1.26 1.16 1.54 1.56 1.58 1.34 1.77 1.49
171 1.16 1.13 1.15 1.08 1.00 1.13 1.25 1.16
Mean 1.03 1.03 1.08 1.04 0.95 1.03 1.06 1.03
TT1 TT2 TT3 TT4Random
Number
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TEAC (mM) Raw Data – LHT (n=20) 
 
 
pre end pre end pre end pre end
101 0.73 0.79 0.65 0.82 0.66 0.73 0.79 0.73
104 1.14 0.94 1.29 1.15 0.69 1.37 0.98 1.03
108 0.72 0.90 0.97 0.95 0.81 0.78 0.87 ---
111 1.16 1.21 0.89 1.31 1.24 1.07 1.19 1.17
114 0.62 1.09 0.95 0.71 0.66 0.91 0.76 0.71
115 0.80 0.88 1.04 0.94 0.99 0.98 0.88 0.81
127 0.90 1.02 1.05 0.98 0.86 1.13 1.07 1.16
129 1.14 1.15 1.14 1.08 0.91 1.30 1.40 1.13
132 1.08 1.02 1.13 1.03 0.99 1.04 1.29 1.27
136 0.71 0.76 0.67 0.76 0.67 0.87 0.92 0.84
137 1.05 0.98 0.96 0.79 0.79 1.10 0.96 0.96
140 0.77 0.88 0.79 0.79 0.72 0.79 1.08 0.74
143 1.19 1.15 1.51 1.19 1.30 1.70 1.58 1.83
146 1.21 1.40 1.23 1.15 1.06 1.13 1.08 1.29
150 0.98 1.07 0.74 0.92 0.90 1.05 1.23 0.99
151 0.79 0.71 0.71 0.85 0.88 0.77 0.88 1.06
155 0.29 0.52 0.69 0.65 0.72 0.54 0.61 0.60
158 0.91 0.81 1.23 1.03 1.04 0.73 1.04 1.04
162 1.43 1.16 1.16 0.97 1.08 1.37 1.32 1.03
166 0.85 0.76 1.00 0.93 0.86 1.04 0.86 1.07
Mean 0.92 0.96 0.99 0.95 0.89 1.02 1.04 1.02
TT1 TT2 TT3 TT4Random
Number
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pre end pre end pre end pre end
103 0.54 -0.22 0.52 0.55 0.47 0.52 0.59 0.56
105 0.98 0.85 1.20 1.04 1.15 0.80 0.80 0.98
109 1.04 0.89 1.14 0.91 0.69 1.12 1.13 0.80
112 1.09 1.08 1.01 0.98 0.82 0.85 0.98 0.99
116 0.77 0.85 0.87 0.81 0.73 0.87 0.89 0.86
118 1.14 1.01 1.14 1.21 0.96 1.21 1.39 1.21
122 0.77 0.92 0.99 1.23 1.31 0.98 1.06 1.09
123 0.89 1.24 1.24 1.22 0.98 1.02 0.98 1.22
128 1.10 1.01 1.28 1.25 1.23 0.92 1.02 1.24
130 1.02 1.12 1.05 1.23 0.90 1.00 0.77 1.13
131 1.34 1.28 1.20 1.12 1.09 1.11 1.26 1.33
133 0.86 0.86 0.86 0.98 0.95 0.93 1.10 0.96
138 1.00 0.69 1.10 0.85 0.85 0.73 0.91 0.93
142 1.12 0.96 0.87 0.94 0.85 1.19 1.27 1.12
144 0.95 0.87 0.90 0.86 0.81 1.03 1.09 1.07
145 1.10 0.89 1.50 1.27 1.30 1.03 1.66 1.25
152 0.85 0.79 0.97 1.07 0.92 0.89 1.03 0.96
154 0.65 --- 0.87 0.91 0.85 0.86 0.99 0.84
156 0.73 0.68 0.82 0.77 0.72 0.93 0.66 0.90
159 1.19 0.85 0.69 0.57 0.91 0.96 0.98 0.96
167 0.95 0.94 1.16 1.16 1.22 1.18 0.89 1.32
172 1.03 1.03 0.86 1.05 0.84 1.00 1.09 0.93
Mean 0.96 0.88 1.01 1.00 0.93 0.96 1.02 1.03
Random
Number




oxLDL (ng/ml) Raw Data – PLA (n=19) 
pre end pre end pre end pre end
102 112.63 175.55 125.21 92.22 66.61 90.93 61.59 58.56
106 31.07 25.33 41.65 23.95 35.20 36.04 29.99 41.03
107 108.74 89.34 94.45 102.01 102.01 120.67 97.19 113.22
110 11.29 26.13 30.01 24.46 23.10 17.07 18.75 29.86
113 111.75 111.06 112.09 115.18 119.31 114.49 --- 113.12
117 550.78 593.02 366.47 503.34 298.65 339.97 205.24 327.86
120 52.19 49.54 49.81 57.56 43.78 41.73 39.01 46.14
125 104.57 131.69 86.31 103.65 74.49 80.10 76.36 54.74
126 9.77 3.96 11.46 15.10 21.65 28.76 20.68 25.22
139 107.93 147.63 86.41 91.18 74.74 127.80 87.61 100.21
141 593.33 767.97 586.13 719.16 503.81 683.17 624.59 784.04
147 108.07 112.05 --- --- 94.94 113.48 67.07 109.88
148 168.99 199.02 171.14 209.56 190.18 222.92 166.51 210.98
149 68.12 76.28 63.48 67.42 61.20 69.75 60.53 62.53
153 1910.92 2671.23 1941.63 2510.55 2815.09 2674.43 2386.77 2331.53
157 29.29 37.64 23.61 37.30 25.75 36.61 31.40 29.24
160 33.78 30.76 23.41 19.62 22.89 26.63 27.65 46.21
161 100.78 101.62 91.94 94.03 89.30 108.61 93.62 103.62
171 123.98 148.08 114.63 80.95 74.29 46.60 55.05 88.94
Mean 228.31 289.36 223.32 270.40 249.32 262.09 230.53 246.15
Random
Number
TT1 TT2 TT3 TT4
102 
oxLDL (ng/ml) Raw Data – LHT (n=20) 
pre end pre end pre end pre end
101 27.69 28.72 48.72 66.52 363.18 584.40 328.31 505.86
104 122.50 120.54 56.40 106.03 89.20 139.81 109.12 116.03
108 259.56 258.36 245.57 211.36 146.63 244.68 240.22 ---
111 266.06 246.57 169.16 210.37 168.12 197.13 166.71 312.47
114 66.22 68.32 52.94 55.51 62.34 62.62 46.37 77.65
115 64.94 83.66 25.31 52.96 38.63 38.72 29.09 54.02
127 29.73 18.48 22.95 21.64 9.45 17.74 8.11 11.11
129 28.70 41.24 32.83 22.04 22.88 26.69 0.00 23.78
132 301.03 285.44 261.92 233.10 242.59 264.69 213.07 287.90
136 70.51 40.10 48.14 41.92 21.93 45.07 41.49 37.33
137 1942.14 1623.35 1811.73 1932.98 1860.17 1745.68 2007.09 2341.54
140 40.07 44.39 32.15 28.75 23.21 28.91 23.07 30.19
143 91.11 100.79 61.04 78.18 77.73 85.56 71.54 89.41
146 11.63 11.38 10.24 11.17 9.33 6.69 10.13 22.06
150 130.80 139.93 89.03 149.67 113.56 113.48 135.36 140.87
151 204.92 214.68 162.25 155.36 167.22 194.29 182.97 228.88
155 118.86 126.85 102.98 109.44 91.64 114.12 105.03 102.10
158 183.23 221.73 125.12 238.72 187.93 225.07 273.40 235.44
162 885.05 606.60 582.13 776.05 453.42 649.36 598.76 600.76
166 95.40 97.51 39.31 33.73 39.67 30.57 19.17 62.43
Mean 247.01 218.93 199.00 226.78 209.44 240.76 230.45 277.89
Random
Number
TT1 TT2 TT3 TT4
103 
oxLDL (ng/ml) Raw Data – HHT (n=22) 
 
pre end pre end pre end pre end
103 13.16 15.11 14.60 12.31 19.48 17.41 11.72 24.38
105 6.76 7.12 4.56 7.53 5.37 6.15 4.39 3.44
109 19.30 13.42 7.48 12.10 24.05 17.19 19.24 19.21
112 24.63 14.74 16.15 16.87 19.36 20.44 19.36 33.76
116 409.40 499.78 425.27 524.61 472.27 512.77 402.92 389.07
118 40.42 66.74 42.48 69.31 73.78 97.26 68.99 57.64
122 334.92 338.47 324.63 319.73 286.50 376.69 305.18 281.22
123 17.39 3.78 4.53 7.83 10.75 0.00 0.00 4.43
128 36.44 21.49 35.48 56.05 37.40 38.67 42.80 49.44
130 398.25 494.54 524.03 568.03 426.11 403.54 448.15 501.74
131 98.39 105.81 95.61 113.19 54.81 95.61 97.09 98.39
133 114.38 119.51 118.38 86.37 122.59 121.62 95.10 88.78
138 934.60 1650.49 1197.20 1306.51 1424.63 1116.44 690.16 1030.76
142 7.19 10.31 12.16 13.23 0.00 1.70 0.00 0.51
144 198.65 230.99 179.19 225.72 205.71 204.87 152.64 200.76
145 36.45 16.95 17.81 16.00 6.34 6.48 23.59 12.42
152 208.94 228.42 180.44 223.78 177.66 247.25 214.20 216.06
154 140.96 --- 117.93 142.33 111.40 135.11 136.83 108.66
156 12.90 15.54 14.05 15.70 8.48 15.39 15.48 15.54
159 204.33 200.58 225.06 179.48 95.34 200.58 247.24 417.27
167 2666.57 2398.42 1881.93 2260.42 1142.71 1707.20 1502.60 1526.57
172 35.99 16.22 9.83 14.57 11.76 12.65 8.81 25.25
Mean 270.91 308.02 247.67 281.44 215.30 243.41 204.84 232.06
Random
Number
TT1 TT2 TT3 TT4
104 
CRP 
CRP (mg/L) Raw Data – PLA (n=19) 
pre end pre end pre end pre end
102 0.51 0.38 0.44 0.57 0.45 0.46 0.79 0.82
106 0.42 0.43 0.33 0.33 0.53 0.60 0.72 0.73
107 0.31 0.32 0.29 0.31 0.34 0.37 0.46 0.46
110 0.23 0.25 0.22 0.23 0.21 0.22 0.24 0.24
113 1.16 1.11 1.29 1.46 0.70 0.88 0.97 1.19
117 2.35 2.54 2.22 2.47 4.34 5.09 4.39 4.87
120 0.59 0.62 3.36 3.58 0.61 0.61 0.58 0.68
125 0.34 0.33 0.36 0.34 0.43 0.40 0.38 0.39
126 0.54 0.60 0.66 0.65 2.53 2.84 1.96 2.03
139 0.38 0.39 0.71 1.06 0.54 0.56 0.77 0.93
141 0.84 0.95 0.51 0.58 1.48 1.74 2.89 3.33
147 6.07 7.21 --- --- 0.49 0.56 0.72 0.88
148 1.03 1.34 1.42 1.17 1.11 1.39 1.93 1.96
149 0.99 1.07 1.72 1.89 1.27 1.17 3.65 4.08
153 2.01 2.25 0.97 1.00 1.62 1.71 1.65 2.17
157 0.96 1.29 0.99 0.92 6.81 7.24 9.03 10.23
160 1.39 1.59 0.61 0.66 1.97 1.77 1.53 1.73
161 0.58 0.61 0.50 0.58 0.43 0.43 0.76 0.78
171 0.84 0.88 1.99 2.20 1.63 2.75 5.89 6.21
Mean 1.13 1.27 1.03 1.11 1.45 1.62 2.07 2.30
Random
Number
TT1 TT2 TT3 TT4
105 
CRP (mg/L) Raw Data – LHT (n=20) 
pre end pre end pre end pre end
101 0.60 0.68 0.58 0.64 2.13 2.40 2.16 2.46
104 0.33 0.33 10.36 9.80 0.92 0.97 0.62 0.69
108 0.38 0.42 0.35 0.34 1.62 1.68 0.95 ---
111 0.44 0.49 0.45 0.53 1.32 1.43 2.50 2.06
114 0.37 0.40 0.50 0.50 0.39 0.43 0.47 0.54
115 0.62 0.68 0.41 0.43 0.36 0.42 0.71 1.00
127 0.56 0.61 0.39 0.45 4.77 4.56 4.09 4.40
129 2.48 2.69 1.23 1.19 1.27 1.51 1.35 1.46
132 0.39 0.43 0.26 0.29 0.35 0.34 0.36 0.42
136 2.79 2.91 1.40 1.47 1.08 0.97 1.07 1.19
137 0.86 0.93 0.85 0.95 1.45 1.60 4.11 4.06
140 0.39 0.42 0.61 0.69 0.69 0.73 0.88 0.93
143 1.02 1.16 0.56 0.59 3.88 4.48 3.32 3.55
146 1.05 1.09 0.76 0.76 1.08 1.32 1.34 1.51
150 0.56 0.59 0.47 0.48 0.85 0.98 1.12 1.22
151 0.38 0.46 5.62 6.48 0.37 0.38 0.42 0.44
155 1.71 2.14 2.33 2.26 2.16 1.97 2.35 2.66
158 1.05 1.19 1.39 1.39 0.71 0.85 1.23 1.34
162 0.33 0.40 0.34 0.37 0.37 0.40 0.42 0.43
166 2.73 2.94 1.97 1.90 4.19 4.48 4.89 5.62
Mean 0.95 1.05 1.54 1.58 1.50 1.60 1.72 1.89
Random
Number
TT1 TT2 TT3 TT4
106 
CRP (mg/L) Raw Data – HHT (n=22) 
 
pre end pre end pre end pre end
103 2.54 2.86 1.58 1.61 4.47 6.18 6.01 6.73
105 4.28 4.99 1.18 1.12 0.66 0.80 1.54 1.95
109 0.50 0.53 0.34 0.36 0.70 0.68 0.88 0.86
112 0.90 1.18 1.47 1.39 0.64 0.70 1.23 1.24
116 0.51 0.45 0.74 0.87 0.46 0.43 1.29 1.43
118 0.30 0.33 0.38 0.41 0.38 0.38 0.75 0.84
122 0.49 0.63 0.40 0.40 0.65 0.75 0.79 0.83
123 2.00 2.27 0.84 0.97 0.96 0.95 0.56 0.71
128 1.24 1.45 0.55 0.69 0.39 0.43 0.47 0.49
130 0.22 0.23 0.22 0.24 0.36 0.43 0.36 0.37
131 0.46 0.53 0.54 0.59 0.42 0.43 0.65 0.74
133 0.67 0.74 0.71 0.82 1.03 1.13 1.52 1.58
138 0.38 0.38 0.75 0.76 0.46 0.49 0.61 0.72
142 1.98 2.48 0.76 0.62 0.76 0.86 1.10 1.19
144 0.39 0.40 0.29 0.31 0.54 0.57 0.46 0.52
145 1.72 1.92 1.74 2.28 1.01 1.34 2.38 2.30
152 2.65 3.60 2.38 2.36 0.96 1.19 1.06 1.22
154 0.83 --- 0.74 0.99 0.80 1.15 1.36 1.25
156 0.39 0.41 0.35 0.44 0.37 0.39 0.30 0.34
159 5.82 6.77 4.65 5.84 4.56 6.05 5.84 6.99
167 11.00 12.93 4.79 5.43 0.52 0.52 0.74 0.85
172 0.62 0.60 0.39 0.39 0.44 0.47 0.80 0.84
Mean 1.81 2.18 1.17 1.31 0.98 1.20 1.40 1.55
Random
Number
TT1 TT2 TT3 TT4
107 
8IP 
8IP (pg/ml) Raw Data – PLA (n=19) 
pre end pre end pre end pre end
102 25.49 38.75 33.00 36.06 36.18 43.08 29.60 27.23
106 32.05 24.70 22.95 40.15 28.40 26.28 23.08 26.13
107 25.73 23.40 20.18 33.13 22.60 28.85 19.53 26.20
110 29.80 25.03 23.98 24.20 32.00 27.58 27.58 24.05
113 26.05 16.40 27.40 18.93 21.03 22.15 17.05 23.40
117 34.15 25.18 24.45 31.35 29.80 34.35 22.95 30.95
120 37.10 26.78 43.26 33.69 36.03 32.36 23.07 32.73
125 30.75 36.96 31.91 38.21 34.37 34.71 34.89 43.40
126 47.58 38.27 33.96 38.39 30.74 40.22 31.59 37.40
139 46.83 41.48 34.38 47.48 44.34 49.64 42.71 55.31
141 45.84 45.96 40.31 41.10 47.58 55.53 48.84 33.96
147 37.23 61.71 --- --- 30.36 36.70 50.91 33.56
148 25.20 27.47 33.50 23.58 27.93 14.21 21.30 26.70
149 39.08 48.41 33.93 41.13 41.60 48.63 37.64 41.60
153 54.93 63.55 40.30 27.58 38.23 39.33 24.85 41.33
157 25.25 21.35 20.70 30.33 25.70 22.83 21.13 20.80
160 12.55 10.35 11.70 12.93 10.78 10.95 11.85 9.53
161 49.61 44.97 47.58 56.10 48.08 53.43 44.30 50.93
171 45.48 44.12 44.12 45.72 39.00 49.56 44.12 49.43
Mean 35.30 34.99 31.53 34.45 32.88 35.28 30.37 33.40
Random
Number
TT1 TT2 TT3 TT4
108 
8IP (pg/ml) Raw Data – LHT (n=20) 
pre end pre end pre end pre end
101 20.63 18.68 22.23 23.35 30.35 29.03 18.55 24.70
104 21.35 23.80 26.95 20.90 21.68 22.83 19.63 25.48
108 20.98 26.75 34.93 29.18 22.40 27.65 23.18 ---
111 17.93 21.35 20.33 23.95 24.70 28.23 18.05 23.40
114 42.93 39.80 43.88 41.08 28.95 34.68 32.15 36.35
115 27.55 28.78 25.90 28.00 25.55 27.85 26.20 31.75
127 22.98 31.68 29.81 25.38 26.40 25.44 24.66 31.04
129 33.45 35.18 40.46 34.65 28.44 33.12 31.98 26.46
132 33.68 34.11 38.40 27.27 42.41 33.24 31.32 28.79
136 25.80 28.34 59.49 30.74 29.66 28.47 29.66 37.05
137 50.09 54.56 51.71 44.00 47.66 43.55 34.34 38.72
140 44.34 39.69 40.19 40.70 44.22 53.82 40.89 44.34
143 28.95 38.00 39.90 41.70 37.10 32.79 27.30 40.89
146 35.54 43.70 39.74 41.16 34.44 34.83 36.87 40.32
150 46.95 43.62 54.65 77.43 45.45 48.41 50.76 47.28
151 26.90 19.48 34.73 14.85 23.33 23.93 26.10 26.43
155 24.23 21.53 24.53 21.40 22.55 21.88 24.73 22.28
158 22.98 29.40 35.68 25.03 23.35 24.05 29.30 23.60
162 49.85 49.56 39.54 45.57 35.90 42.36 36.77 54.69
166 41.58 36.77 40.28 35.82 38.63 41.15 39.14 43.05
Mean 31.93 33.24 37.16 33.61 31.66 32.86 30.08 34.03
Random
Number
TT1 TT2 TT3 TT4
109 
8IP (pg/ml) Raw Data – HHT (n=22) 
 
pre end pre end pre end pre end
103 13.18 7.50 9.80 15.25 11.00 12.03 8.05 11.53
105 38.18 22.55 24.23 28.15 19.55 25.75 24.78 27.35
109 29.85 30.50 31.95 22.23 23.68 29.85 32.15 26.20
112 15.20 26.80 25.20 29.78 24.78 27.09 32.79 51.90
116 21.18 21.55 30.88 26.33 20.35 23.33 24.55 29.70
118 28.85 29.13 22.85 28.02 26.70 25.83 27.23 27.75
122 35.07 27.66 32.60 30.74 30.57 31.77 47.13 43.08
123 37.32 34.38 40.10 41.96 46.04 46.62 41.84 27.54
128 28.29 27.93 26.79 25.08 27.66 31.04 23.78 29.37
130 48.23 38.19 34.13 52.37 29.85 38.99 36.27 48.65
131 45.05 56.03 43.61 43.20 29.03 39.45 33.39 56.60
133 38.12 38.33 39.96 35.91 34.04 42.71 39.14 46.44
138 39.44 41.33 38.39 44.18 40.43 41.33 38.18 42.96
142 38.73 32.58 32.25 30.78 30.60 45.45 27.87 48.41
144 31.74 29.76 28.05 43.19 35.87 39.32 38.55 35.52
145 47.21 44.01 40.71 37.73 38.24 35.79 38.24 46.77
152 56.93 43.08 43.65 39.43 35.18 48.63 47.13 39.25
154 24.85 --- 22.50 35.30 31.65 20.90 12.90 24.93
156 25.63 24.65 35.75 25.93 24.15 26.03 19.20 24.60
159 27.80 26.39 24.53 32.88 27.23 23.60 24.63 20.28
167 32.54 39.21 37.35 40.44 40.65 38.61 38.31 38.42
172 34.62 39.11 35.60 44.24 37.92 31.76 40.13 41.30
Mean 33.54 32.41 31.86 34.23 30.23 32.99 31.65 35.84
Random
Number
TT1 TT2 TT3 TT4
110 
TNFα 
TNFα (pg/ml) Raw Data – PLA (n=19) 
pre end pre end pre end pre end
102 4.80 5.57 44.75 54.30 21.38 31.56 21.07 29.41
106 3.21 3.81 3.37 4.18 3.64 5.17 4.17 5.18
107 5.92 5.14 4.45 5.21 5.11 6.87 5.35 4.58
110 5.45 5.11 9.73 8.84 10.58 14.38 12.59 16.77
113 1.81 1.89 1.85 3.01 2.14 2.11 3.09 2.36
117 8.00 10.20 6.46 8.10 8.15 8.81 6.23 8.23
120 6.31 6.96 7.35 8.48 4.31 6.05 4.75 4.89
125 10.53 12.49 10.15 12.35 10.27 11.55 12.70 12.17
126 6.03 7.11 5.57 7.32 7.80 8.44 6.21 8.23
139 4.51 5.18 3.85 5.29 4.45 5.81 4.65 4.53
141 3.40 4.25 2.71 4.28 2.90 4.00 2.88 4.13
147 6.32 7.90 --- --- 5.56 7.41 5.33 7.73
148 2.05 2.51 1.82 1.92 1.33 1.97 1.72 1.65
149 5.66 6.97 6.37 8.92 5.50 8.17 6.13 8.62
153 12.93 27.13 7.70 27.64 23.24 16.13 10.53 23.52
157 3.66 4.51 4.83 4.86 3.32 4.20 3.29 3.92
160 7.14 9.74 6.63 7.14 6.74 10.52 6.92 8.55
161 5.76 6.87 5.74 6.86 5.84 6.67 6.02 6.41
171 2.72 3.70 3.01 3.76 2.31 3.77 2.52 3.57
Mean 5.59 7.21 7.57 10.14 7.08 8.61 6.64 8.66
Random
Number
TT1 TT2 TT3 TT4
111 
TNFα (pg/ml) Raw Data – LHT (n=20) 
pre end pre end pre end pre end
101 6.94 6.38 5.36 5.91 5.24 6.88 5.36 6.37
104 7.40 6.72 7.76 8.68 7.74 8.33 8.24 7.51
108 8.05 10.84 7.07 9.81 12.39 12.92 9.75 ---
111 4.56 5.55 4.07 4.24 3.31 4.86 3.40 4.78
114 9.12 12.61 6.87 9.58 7.78 9.11 6.26 8.35
115 5.57 9.37 8.01 12.58 6.74 10.45 6.83 10.02
127 4.00 4.97 4.66 4.74 4.89 5.41 4.93 7.83
129 5.47 6.85 4.22 5.26 5.81 6.03 4.71 5.38
132 4.48 5.92 3.45 4.00 4.92 4.69 4.58 5.15
136 8.17 7.39 6.33 7.99 6.08 7.68 8.16 8.52
137 7.34 8.31 9.56 11.97 7.58 9.40 6.93 11.26
140 4.66 5.19 4.48 4.85 3.24 4.16 3.42 4.06
143 5.77 8.06 5.05 6.58 4.28 5.61 4.01 5.26
146 9.42 10.28 6.26 8.73 7.19 8.79 5.91 8.24
150 8.10 8.08 8.33 11.27 13.24 12.04 9.93 12.49
151 7.72 7.69 7.20 6.77 6.05 7.47 6.02 6.69
155 8.62 10.75 6.85 6.94 7.35 6.15 6.29 6.24
158 9.81 11.90 8.52 13.59 8.75 12.62 7.86 12.46
162 4.87 5.59 4.18 6.07 4.78 5.88 4.63 5.37
166 3.67 4.18 2.43 2.97 2.93 3.10 2.09 2.83
Mean 6.69 7.83 6.03 7.63 6.51 7.58 5.97 7.31
Random
Number
TT1 TT2 TT3 TT4
112 
TNFα (pg/ml) Raw Data – HHT (n=22) 
pre end pre end pre end pre end
103 7.97 7.48 5.22 5.59 6.79 7.51 5.58 6.64
105 4.98 6.59 5.64 7.05 4.66 6.92 6.02 7.18
109 5.84 5.90 5.53 7.32 6.34 7.83 5.92 8.94
112 4.92 4.53 3.17 3.93 3.33 3.97 3.42 4.56
116 6.17 6.01 5.75 7.11 4.55 8.75 7.03 8.08
118 7.03 9.99 5.00 5.89 4.56 5.92 5.18 6.36
122 7.19 9.05 6.10 8.57 5.37 7.02 6.25 7.42
123 4.06 5.63 2.57 4.27 3.33 3.91 4.07 4.18
128 8.30 11.12 9.01 11.20 6.90 9.90 7.26 11.07
130 6.49 7.78 5.60 6.78 7.12 8.32 6.47 7.51
131 4.80 9.44 4.18 6.66 4.96 6.80 5.65 4.39
133 2.36 2.45 1.78 2.12 1.87 2.09 1.95 1.76
138 4.31 6.35 3.12 4.60 3.17 3.74 3.02 3.56
142 5.21 5.60 4.83 6.23 4.92 6.03 7.46 8.08
144 4.42 7.45 5.89 7.97 4.67 6.55 4.82 7.52
145 5.54 9.53 5.62 7.59 5.73 6.21 5.30 6.44
152 4.54 5.08 4.51 6.12 3.87 6.13 4.20 5.76
154 2.99 --- 3.39 3.54 4.49 7.09 4.82 6.04
156 5.13 5.50 4.62 4.29 3.63 4.49 4.18 4.14
159 13.26 15.85 14.10 18.14 16.05 15.52 15.91 17.61
167 5.93 6.36 5.42 6.73 3.63 4.57 3.87 4.39
172 9.05 9.42 7.12 8.93 7.08 7.39 5.97 5.94
Mean 5.93 7.48 5.37 6.85 5.32 6.67 5.65 6.71
Random
Number




IL-6 (pg/ml) Raw Data – PLA (n=19) 
pre end pre end pre end pre end
102 1.52 4.49 70.79 103.00 32.85 55.30 30.77 40.95
106 5.62 7.40 4.86 6.84 5.59 7.70 4.90 7.44
107 4.08 3.68 4.11 5.51 5.19 7.67 5.20 4.88
110 0.20 0.97 8.88 6.75 15.54 23.94 13.49 24.41
113 2.58 7.94 2.42 5.16 1.77 6.71 3.45 6.13
117 2.67 11.03 1.94 6.58 1.84 5.81 1.41 6.26
120 0.23 2.73 0.77 2.70 0.23 1.44 0.34 1.22
125 0.62 2.56 0.94 2.91 0.67 2.13 0.93 2.24
126 0.92 3.91 0.66 3.10 1.39 3.80 0.96 3.46
139 2.02 4.06 2.02 5.80 1.89 4.67 1.62 2.42
141 7.89 8.42 4.58 4.99 4.88 5.14 3.69 5.16
147 1.79 4.65 --- --- 1.67 5.52 1.43 4.53
148 0.27 2.49 0.62 1.05 0.27 1.68 0.62 1.78
149 0.25 2.89 2.01 5.53 0.19 2.10 0.53 1.77
153 13.66 34.33 6.44 28.95 24.02 20.14 10.45 22.66
157 0.37 2.06 0.59 2.37 2.50 3.68 0.68 1.84
160 2.02 4.30 2.05 5.02 1.94 15.43 2.36 6.00
161 8.56 13.07 11.37 9.86 14.72 11.42 10.38 10.87
171 1.92 4.70 3.85 6.79 2.05 10.88 0.70 4.69
Mean 3.01 6.61 7.16 11.83 6.27 10.27 4.94 8.35
Random
Number
TT1 TT2 TT3 TT4
114 








pre end pre end pre end pre end
101 0.56 0.97 0.76 1.12 0.81 2.05 0.56 1.62
104 0.31 0.96 0.49 2.28 0.00 1.21 0.51 0.68
108 11.21 10.40 12.70 9.51 8.61 8.65 4.17 ---
111 1.00 2.22 1.17 4.53 0.48 10.73 0.47 3.33
114 0.39 4.47 0.15 4.95 0.27 1.89 0.42 2.49
115 0.55 4.47 0.78 6.42 0.49 5.85 0.36 1.38
127 5.33 7.09 5.93 7.26 5.77 6.45 6.18 10.71
129 0.69 1.44 0.39 1.86 2.15 2.69 0.42 1.15
132 7.54 11.72 6.06 8.74 9.86 10.43 6.85 11.64
136 46.32 43.49 39.07 41.52 38.38 42.21 43.91 42.01
137 1.45 2.82 1.28 3.20 0.94 3.00 1.01 3.46
140 0.64 2.98 1.88 4.03 0.99 4.17 1.34 3.92
143 0.64 1.64 0.47 1.86 0.65 1.63 0.77 2.00
146 15.20 16.87 10.47 17.87 20.64 30.58 20.32 29.38
150 4.19 5.23 5.54 7.52 11.62 13.00 8.68 10.17
151 1.66 5.37 2.39 5.48 0.63 3.31 2.36 3.84
155 0.93 4.16 0.26 2.86 0.67 1.95 0.49 1.99
158 0.59 2.22 0.07 2.04 0.10 1.60 0.02 1.32
162 0.80 4.86 0.71 4.25 0.71 3.90 1.02 2.62
166 1.77 5.37 2.87 3.62 5.43 8.58 3.60 6.93
Mean 5.09 6.94 4.67 7.05 5.46 8.19 5.17 7.40
Random
Number
TT1 TT2 TT3 TT4
115 
IL-6 (pg/ml) Raw Data – HHT (n=22) 
pre end pre end pre end pre end
103 1.91 2.61 1.86 3.09 2.43 5.21 1.98 3.49
105 0.45 3.60 0.81 2.49 0.39 3.05 0.82 1.94
109 1.15 3.11 0.93 4.31 1.91 5.46 1.52 4.57
112 33.12 36.78 18.72 23.83 14.76 18.64 15.56 16.50
116 2.97 7.42 2.28 9.87 1.66 15.82 2.55 7.33
118 1.23 4.92 0.99 4.84 1.06 4.52 2.13 5.41
122 1.01 3.11 0.76 2.99 0.80 2.36 1.19 3.08
123 2.41 5.39 2.02 3.72 2.01 3.75 3.98 5.26
128 1.82 5.61 1.93 7.06 2.30 5.07 2.30 6.91
130 2.40 5.58 2.34 4.24 2.40 4.02 2.53 3.36
131 6.55 13.97 7.17 11.64 7.16 13.35 6.21 5.05
133 30.29 27.50 13.79 17.54 10.10 15.59 14.06 11.57
138 3.19 5.86 2.84 3.96 2.10 3.82 2.62 4.39
142 0.29 2.38 0.40 2.56 0.51 2.73 0.87 1.58
144 1.26 2.63 1.26 4.64 1.73 3.91 1.56 3.14
145 1.14 9.61 1.62 5.87 0.85 6.45 0.63 5.40
152 9.62 9.33 9.26 10.63 9.94 13.37 10.69 13.75
154 0.51 --- 0.49 4.27 0.50 5.38 0.92 3.32
156 6.22 7.06 5.42 7.29 3.31 7.36 3.63 6.38
159 21.73 24.73 23.04 30.37 25.11 27.33 30.59 35.96
167 10.04 13.63 7.98 10.40 8.72 10.06 6.28 11.33
172 2.55 4.36 1.61 3.47 2.32 5.21 3.98 7.47
Mean 6.45 9.49 4.89 8.14 4.64 8.29 5.30 7.60
Random
Number
TT1 TT2 TT3 TT4
116 
IL-10 
IL-10 (pg/ml) Raw Data – PLA (n=19) 
pre end pre end pre end pre end
102 9.56 25.46 341.00 829.00 139.00 340.00 162.00 239.00
106 26.99 28.77 27.90 31.34 26.07 37.55 22.58 33.69
107 43.05 39.29 50.49 40.86 54.99 60.37 60.01 45.83
110 7.27 5.48 62.45 59.33 112.00 124.00 93.12 127.00
113 6.77 11.64 7.38 7.38 6.42 7.78 6.24 8.76
117 14.19 18.06 16.30 14.94 10.96 16.90 15.14 19.85
120 7.40 9.14 8.57 8.15 8.05 8.81 8.81 8.15
125 11.20 14.46 13.38 12.72 15.32 12.68 13.64 13.12
126 4.38 8.86 3.20 13.94 4.78 6.73 4.87 9.44
139 12.39 16.37 11.81 20.48 14.16 21.88 16.30 15.97
141 239.00 288.00 119.00 146.00 114.00 140.00 120.00 132.00
147 40.80 36.31 --- --- 25.46 29.46 27.25 27.60
148 5.82 13.36 10.15 11.86 5.86 8.43 7.26 6.94
149 1.25 6.54 0.90 4.18 0.65 3.56 0.38 0.50
153 23.24 63.33 9.70 80.43 36.70 27.76 18.02 36.70
157 9.57 12.64 8.36 8.91 9.90 9.28 6.43 9.35
160 21.31 24.66 18.09 19.66 22.10 65.05 26.06 29.90
161 23.81 31.44 31.44 31.98 17.16 18.68 13.03 14.80
171 19.30 30.67 26.69 31.27 15.04 19.78 14.66 17.30
Mean 27.75 36.03 42.60 76.25 33.61 50.46 33.46 41.89
Random
Number
TT1 TT2 TT3 TT4
117 
IL-10 (pg/ml) Raw Data – LHT (n=20) 
pre end pre end pre end pre end
101 10.96 10.01 6.41 7.47 10.92 13.49 11.41 12.49
104 14.66 10.59 18.53 18.61 13.60 12.56 14.88 9.70
108 20.04 17.59 18.89 29.42 112.00 194.00 31.10
111 12.05 8.14 13.45 11.78 8.90 18.61 8.27 11.41
114 17.41 35.95 14.89 32.17 14.29 15.09 14.79 33.92
115 8.00 27.56 12.07 21.84 6.38 20.80 7.61 5.71
127 13.01 9.19 12.92 10.18 12.79 14.17 15.99 20.84
129 0.35 0.96 0.11 1.26 6.24 4.01 0.35 0.27
132 39.41 51.91 33.44 34.13 48.01 45.18 40.93 50.95
136 331.00 297.00 362.00 409.00 292.00 315.00 372.00 368.00
137 5.16 10.86 7.60 7.41 17.20 16.96 13.50 13.02
140 17.32 15.56 16.27 12.53 14.06 14.84 13.27 12.96
143 1.79 3.67 2.44 2.22 1.37 2.05 2.14 2.14
146 146.00 150.00 62.15 83.06 82.83 98.21 78.27 105.00
150 3.46 5.27 4.23 6.12 6.49 6.96 5.23 5.37
151 4.75 8.84 11.71 8.17 2.54 4.88 3.97 5.89
155 19.26 40.64 10.19 15.80 14.03 14.62 15.21 15.55
158 12.05 10.11 6.61 10.94 6.57 10.19 7.51 12.50
162 8.96 14.61 6.37 11.41 5.57 11.73 6.59 7.95
166 11.51 12.80 8.80 7.55 12.85 18.86 11.62 19.54
Mean 34.86 37.06 31.45 37.05 34.43 42.61 33.73 37.54
Random
Number
TT1 TT2 TT3 TT4
118 
IL-10 (pg/ml) Raw Data – HHT (n=22) 
pre end pre end pre end pre end
103 3.91 5.67 3.99 5.92 5.71 5.27 6.28 3.43
105 10.30 24.95 8.11 14.67 6.21 16.67 8.36 13.48
109 2.60 3.51 3.67 3.21 5.92 7.66 4.59 6.59
112 423.00 325.00 56.05 70.64 82.58 95.89 84.39 85.06
116 9.83 31.93 11.17 21.22 5.98 20.83 10.55 17.30
118 10.03 16.15 10.52 13.53 9.50 14.03 11.48 11.43
122 3.02 5.06 3.32 8.96 2.78 4.53 3.71 5.97
123 63.04 84.98 29.65 37.89 33.69 42.14 54.52 57.66
128 14.68 22.43 19.27 22.19 15.19 17.64 14.13 30.23
130 27.64 45.88 18.25 20.79 34.82 27.42 29.98 40.21
131 47.47 87.02 45.29 56.63 45.66 71.73 45.00 38.78
133 783.00 602.00 301.00 339.00 233.00 345.00 306.00 238.00
138 13.33 19.72 9.85 16.30 11.70 13.69 19.44 21.27
142 4.40 6.90 8.83 9.93 7.82 8.74 8.93 6.95
144 16.07 19.40 15.90 21.66 17.29 18.68 17.64 24.90
145 8.35 28.48 8.75 17.41 6.45 14.03 8.80 11.88
152 11.08 8.84 8.21 10.37 9.20 10.05 8.21 9.16
154 4.71 --- 5.09 5.48 37.03 29.46 43.11 43.24
156 17.32 20.51 18.15 24.02 13.04 28.25 16.77 17.35
159 72.66 90.08 84.48 121.00 87.93 102.00 117.00 167.00
167 43.50 41.12 65.43 71.66 25.30 29.66 27.39 31.29
172 15.81 17.34 6.80 15.81 12.06 14.42 9.71 19.73
Mean 72.99 71.76 33.72 42.20 32.22 42.63 38.91 40.95
Random
Number
TT1 TT2 TT3 TT4
119 
IL-1β 
IL-1β (pg/ml) Raw Data – PLA (n=19) 
pre end pre end pre end pre end
102 0.02 0.04 32.31 36.12 14.65 18.33 13.64 19.48
106 1.02 0.83 1.03 0.89 0.96 1.12 0.92 1.32
107 0.61 0.29 0.59 0.28 1.41 1.52 0.93 0.53
110 0.09 0.07 5.52 3.72 6.37 8.31 6.24 9.50
113 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
117 0.32 0.53 0.20 0.15 0.26 0.29 0.14 0.15
120 0.15 0.14 0.18 0.16 0.20 0.22 0.16 0.18
125 0.10 0.13 0.05 0.08 0.08 0.10 0.17 0.08
126 0.39 0.38 0.37 0.48 0.88 0.58 0.17 0.30
139 0.72 0.55 0.60 0.68 0.62 0.69 0.49 0.49
141 3.34 2.47 1.24 1.61 1.33 0.92 0.98 1.30
147 0.00 0.01 --- --- 0.02 0.01 0.01 0.01
148 0.06 0.02 0.15 0.10 0.07 0.06 0.07 0.07
149 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
153 0.28 3.08 0.06 3.19 1.83 0.54 0.27 1.31
157 0.21 0.22 0.22 0.23 0.21 0.21 0.13 0.17
160 0.07 0.11 0.12 0.11 0.09 0.13 0.09 0.09
161 0.20 0.68 0.39 0.58 0.45 0.33 0.23 0.26
171 0.06 0.12 0.03 0.03 0.01 0.05 0.02 0.03
Mean 0.40 0.51 2.39 2.69 1.55 1.76 1.30 1.86
Random
Number
TT1 TT2 TT3 TT4
120 
IL-1β (pg/ml) Raw Data – LHT (n=20) 
pre end pre end pre end pre end
101 0.24 0.21 0.24 0.09 0.17 0.22 0.19 0.24
104 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
108 0.05 0.01 0.05 0.10 0.01 0.03 0.01 ---
111 0.00 0.00 0.03 0.03 0.02 0.05 0.02 0.03
114 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
115 0.00 0.01 0.02 0.03 0.01 0.01 0.00 0.01
127 1.47 1.69 2.14 1.49 1.83 1.24 1.41 3.44
129 0.16 0.23 0.15 0.19 0.25 0.14 0.13 0.14
132 0.38 0.37 1.16 1.18 2.02 2.19 0.44 1.50
136 0.27 0.31 0.31 0.47 0.25 0.19 0.31 0.36
137 0.01 0.04 0.02 0.03 0.01 0.00 0.00 0.01
140 0.00 0.05 0.04 0.06 0.08 0.05 0.02 0.07
143 0.01 0.02 0.03 0.02 0.03 0.04 0.04 0.08
146 0.15 0.16 0.01 0.12 0.25 0.40 0.22 0.36
150 1.15 0.76 1.92 3.03 5.22 4.07 3.03 3.90
151 0.13 0.06 0.15 0.02 0.02 0.03 0.07 0.02
155 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
158 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
162 0.49 0.50 0.17 0.76 0.40 0.71 0.48 0.48
166 0.10 0.02 0.07 0.10 0.27 0.50 0.06 0.55
Mean 0.23 0.22 0.33 0.39 0.54 0.49 0.32 0.59
Random
Number
TT1 TT2 TT3 TT4
121 
IL-1β (pg/ml) Raw Data – HHT (n=22) 
pre end pre end pre end pre end
103 0.57 0.57 0.56 0.53 0.53 0.54 0.43 0.38
105 0.08 0.16 0.12 0.19 0.11 0.06 0.11 0.14
109 0.20 0.26 0.19 0.19 0.29 0.26 0.14 0.22
112 0.13 0.18 0.70 0.66 0.54 0.63 0.65 0.45
116 0.08 0.00 0.08 0.03 0.06 0.03 0.03 0.06
118 0.01 0.00 0.04 0.10 0.08 0.19 0.15 0.54
122 0.01 0.01 0.01 0.06 0.02 0.02 0.01 0.06
123 0.06 0.13 0.41 0.82 0.66 0.79 1.22 1.04
128 0.34 1.05 0.32 0.35 0.14 0.37 0.26 1.43
130 0.23 1.31 0.16 0.00 0.05 0.01 0.03 0.11
131 2.26 4.51 1.60 2.65 2.50 3.26 2.50 1.07
133 0.17 0.06 0.53 0.64 0.57 0.54 0.52 0.41
138 0.32 0.52 0.28 0.22 0.29 0.27 0.26 0.56
142 0.01 0.01 0.17 0.10 0.10 0.02 0.03 0.01
144 0.01 0.03 0.04 0.00 0.03 0.03 0.02 0.00
145 0.01 0.09 0.05 0.03 0.01 0.03 0.01 0.03
152 0.41 0.34 0.23 0.52 0.15 0.30 0.21 0.31
154 0.02 --- 0.02 0.01 0.01 0.05 0.01 0.03
156 0.13 0.19 0.06 0.09 0.09 0.27 0.11 0.08
159 3.04 4.36 3.10 5.72 4.62 4.82 4.65 5.03
167 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
172 4.09 3.05 0.23 0.00 3.58 1.89 2.06 2.01
Mean 0.55 0.80 0.40 0.59 0.66 0.65 0.61 0.64
Random
Number
TT1 TT2 TT3 TT4
122 
IL-1ra 
IL-1ra (pg/ml) Raw Data – PLA (n=19) 
pre end pre end pre end pre end
102 0.00 0.00 107.00 173.00 81.13 96.29 84.72 103.00
106 38.63 43.89 42.31 50.22 50.22 50.22 40.73 63.94
107 45.11 47.00 46.37 58.66 61.05 70.43 62.83 68.69
110 78.37 71.23 66.43 88.37 77.78 73.02 76.59 75.41
113 2.19 4.96 0.31 3.30 0.16 2.19 0.97 3.30
117 1.79 6.56 3.21 2.83 2.47 0.44 2.47 8.88
120 42.30 45.46 29.40 30.05 22.83 35.25 35.89 23.49
125 2.87 5.81 3.54 7.91 5.02 5.41 5.41 2.87
126 0.95 1.95 0.74 2.24 0.56 3.90 0.40 1.95
139 22.10 25.87 31.88 37.08 26.63 47.28 34.86 28.13
141 5.75 14.76 10.58 21.90 10.58 9.57 20.23 15.30
147 0.00 0.01 --- --- 0.00 0.54 0.00 11.75
148 6.11 7.93 3.83 10.43 3.83 6.71 2.77 11.07
149 0.00 0.37 0.00 0.09 0.00 0.16 0.00 0.65
153 1.86 4.53 4.96 4.96 1.24 6.78 1.24 5.85
157 17.66 10.97 8.51 16.61 6.18 14.01 6.63 9.48
160 41.59 59.57 20.42 34.84 36.28 42.11 27.29 46.92
161 187.00 170.00 187.00 180.00 203.00 207.00 183.00 166.00
171 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Mean 26.01 27.41 31.47 40.14 31.00 35.33 30.84 34.04
Random
Number
TT1 TT2 TT3 TT4
123 
IL-1ra (pg/ml) Raw Data – LHT (n=20) 
pre end pre end pre end pre end
101 0.00 0.00 0.00 0.00 0.00 21.39 0.00 0.00
104 1.65 1.65 0.68 4.33 0.32 1.94 0.19 0.09
108 9.74 0.66 7.72 3.27 2.69 4.49 1.60 ---
111 0.50 0.72 0.50 0.50 3.30 1.24 0.00 1.24
114 0.00 4.82 0.00 0.66 0.00 2.47 0.00 0.00
115 0.11 1.18 0.00 2.47 0.00 0.66 0.00 2.47
127 16.40 40.12 17.13 22.22 48.43 40.82 35.18 26.57
129 13.63 15.55 20.01 25.13 24.62 26.69 27.74 29.31
132 63.66 68.52 49.68 37.57 49.68 48.47 50.29 46.04
136 35.10 34.55 32.90 28.57 26.44 28.03 25.38 26.44
137 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
140 4.71 6.84 5.23 6.30 4.71 10.28 1.93 6.84
143 3.54 2.89 1.72 4.97 1.72 2.89 1.72 4.97
146 9.71 15.00 11.58 18.56 8.35 13.51 10.17 12.05
150 2.26 4.62 1.71 1.98 5.81 7.99 6.23 5.81
151 1.30 3.20 1.00 0.12 0.00 0.00 0.12 0.48
155 3.60 7.60 3.96 3.60 5.11 5.51 5.11 4.33
158 0.74 1.47 0.05 2.66 0.35 2.66 0.16 0.59
162 34.98 55.68 37.86 52.24 38.43 40.16 35.56 37.86
166 4.71 9.69 11.47 9.69 4.71 10.87 2.35 3.24
Mean 10.32 13.74 10.16 11.24 11.23 13.50 10.19 10.96
Random
Number
TT1 TT2 TT3 TT4
124 
IL-1ra (pg/ml) Raw Data – HHT (n=22)
 
pre end pre end pre end pre end
103 112.00 114.00 93.21 93.74 100.00 93.74 104.00 81.45
105 19.78 22.44 16.09 27.81 15.05 20.84 15.57 24.58
109 24.13 31.52 18.66 15.22 11.78 30.19 12.46 36.78
112 5.19 5.19 10.83 17.52 8.49 15.67 10.83 9.07
116 1.00 2.00 1.30 3.20 0.72 2.78 0.02 1.64
118 0.83 2.55 3.19 4.25 2.86 6.66 1.98 7.99
122 0.00 0.00 0.00 0.37 0.00 0.00 0.00 0.00
123 0.06 6.71 30.05 36.54 34.60 42.30 31.35 42.93
128 7.19 13.51 3.35 16.40 2.77 22.95 12.08 28.02
130 0.00 0.72 0.00 0.00 0.00 0.00 0.00 0.00
131 4.83 10.57 18.73 8.55 10.05 6.16 7.10 12.67
133 0.04 0.65 18.31 20.58 17.56 19.83 22.85 16.80
138 5.86 5.19 7.95 12.31 2.11 8.66 4.53 3.27
142 7.73 7.32 10.30 6.11 3.54 6.11 5.72 8.99
144 26.60 23.59 32.18 32.69 18.67 23.59 19.65 32.18
145 17.60 21.59 10.05 17.60 16.49 16.49 11.09 14.83
152 1.64 3.20 0.12 1.30 0.00 2.38 0.00 0.72
154 4.16 --- 5.19 8.49 7.36 15.05 10.24 7.92
156 5.33 7.12 4.11 8.04 4.44 6.18 5.73 6.75
159 121.00 149.00 110.00 132.00 145.00 153.00 155.00 135.00
167 0.32 5.23 1.54 1.93 0.00 0.32 0.00 0.00
172 0.00 0.00 0.00 0.00 0.00 0.82 0.44 0.00
Mean 16.60 20.58 17.96 21.12 18.25 22.44 19.57 21.44
Random
Number
TT1 TT2 TT3 TT4
125 
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